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Preface 
Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), a member of the TNF 
superfamily, has emerged as a promising anticancer agent, because of its ability to selectively 
kill tumor cells.1 The in vivo administration of TRAIL is proved to be safe, unlike the other 
members of the TNF superfamily. The relative absence of toxic side effects of this naturally 
occurring cytokine, in addition to its antitumor properties, has led to its preclinical evaluation. 
However, despite intensive investigations, little is known regarding the mechanisms underlying 
TRAIL-selectivity or efficiency.2 TRAIL is thought to be important in host tumor surveillance 
and metastasis suppression, and various therapeutic agonists that activate TRAIL receptors to 
induce tumor cell apoptosis are in clinical development.3  TRAIL can bind to two death receptors 
(DRs), DR4 (TRAIL-R1) and DR5 (TRAIL-R2), that contain a cytoplasmic functional death 
domain. In addition, it can bind to two antiapoptotic decoys, DcR1 (TRAIL-R3) and DcR2 
(TRAIL-R4). TRAIL-R3 lacks a cytoplasmic region, and TRAIL-R4 has a truncated non-
functional cytoplasmic death domain. Neither receptor of DcR1 or DcR2, therefore, can mediate 
death signals; rather, they compete with DRs and are considered to act as decoy receptors 
(DcRs).4 It is well-known that there are two essential apoptotic pathways, referred to as the 
death-receptor (extrinsic) pathway and the mitochondrial (intrinsic) pathway (Figure I). TRAIL 
can activate either pathway, depending on the cell type. TRAIL-induced apoptosis initiated by 
the death-receptor pathway involves DR engagement, death-inducing signaling complex (DISC) 
formation, proteolytic activation of caspase-8, and, consequently, activation of caspase-3. 
Proteolytic caspase-8 further activates Bid, which, in turn, translocates to the mitochondria and 
activates the mitochondrial pathway. In the mitochondrial pathway, death signals lead to changes 
in mitochondrial outer membrane permeability, subsequently releasing cytochrome c, which 
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forms an apoptosome with Apaf-1 and caspase-9 and activates an effector caspase, caspase-3. 
However, it has become a problem that considerable numbers of cancer cells, especially some 
highly malignant tumors, are resistant to apoptosis induction by TRAIL.5 For example, lung 
cancer, breast cancer, prostate cancer, gastric cancer, are said to be resistant to TRAIL. 
Resistance to TRAIL can occur at different points in the signaling pathways of TRAIL-induced 
apoptosis.  
 
 
Fig. I TRAIL-mediated apoptotic pathway 
 
Dysfunctions of the death receptors DR4 and DR5 due to mutations can lead to resistance. The 
adaptor protein Fas-associated death domain (FADD) and caspase-8 are essential for assembly of 
the death-inducing signaling complex (DISC), and defects in either of these molecules can lead 
to TRAIL resistance. Over expression of cellular FADD-like interleukin-1β-converting enzyme  
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inhibitory protein (cFLIP) correlates with TRAIL resistance in several types of cancer. Over 
expression of Bcl-2 or Bcl-X(L), loss of Bax or Bak function, high expression of inhibitor of 
apoptosis proteins (IAPs), have also been reported to result in TRAIL resistance. Overcoming 
TRAIL-resistance and understanding the mechanisms underlying such resistance, are, thus very 
important in anticancer drug discovery.6,7  
 
Different chemotherapeutic agents including a number of natural products are reported to have 
TRAIL-resistance overcoming activity. For example, luteolin is a naturally occurring flavone, 
induces apoptosis in various cancer cells. Although little was known concerning the underlying 
molecular mechanisms responsible for this activity, it was revealed recently that the apoptosis by 
luteolin is mediated through death receptor 5 (DR5) up-regulation. Luteolin markedly induced 
the expression of DR5, along with Bcl-2-interacting domain cleavage and the activation of 
caspase-8, -10, -9, and -3, suggesting that DR5 induced by luteolin plays a key role in luteolin-
induced apoptosis. In addition, luteolin induced neither DR5 protein expression nor apoptosis in 
normal human peripheral blood mononuclear cells, implying that luteolin selectively induces 
apoptosis in tumor cells but not in normal cells.8 It was further revealed that the sensitization 
effect of luteolin on TRAIL-induced apoptosis in cancer cells were caused by inhibition of 
protein kinase C and promotion of ubiquitination of X-linked inhibitor of apoptosis protein 
(XIAP) leading to proteasomal degradation.9 Treatment with luteolin, therefore, might be 
promising as a new therapy against cancer.10 Similarly, phytochemicals such as curcumin,11,12 
resveratrol,13 and indole-3-carbinol14 have received attention recently as anticancer agents, since 
it was reported that they augment TRAIL-mediated apoptosis in cancer cells. It was also reported 
that flavopiridol (FP), a semisynthetic compound, sensitized U937 cells to TRAIL through the 
downregulation of XIAP.15 Recent reports suggest that the inhibition of NFkB activity by 
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apigenin,16 a flavone, resulted in a synergistic effect on TNFα-induced apoptosis in a human lung 
cell carcinoma cell line and a prostate cancer cell line, respectively. 2-methoxyestradiol17 are 
also reported to be potent inducers of DR5.  
 
In the recent years, Prof. Ishibashi and his group were exploring natural resources in search for 
bioactive natural products targeting TRAIL signaling pathways. His group identified a number of 
active compounds with TRAIL-resistance overcoming activity, as brandisianin D, BB1, 
fuligocandin B, etc. Brandisianin D is a flavonoid, isolated from the leaves of Milletia 
brandisiana, sensitized human gastric adenocarcinoma (AGS) cells to TRAIL-induced apoptosis 
by upregulating DR5.18 BB1, a dihydroflavonoid, isolated from the leaves of Blumea 
balsamifera, showed TRAIL-resistance overcoming activity by upregulating DR5.19 
Fuligocandin B was isolated from the myxomycete Fuligo candida, and sensitized TRAIL-
resistant leukemia cells to TRAIL-induced apoptosis by upregulating  COX-2 and 15d-PGJ2.20,21 
 
 
 
Fig. II Small molecules having TRAIL-resistance overcoming activity reported by other research groups 
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Fig. III Natural products with TRAIL-resistance overcoming activity reported by Prof. Ishibashi and his 
group 
 
After entering as a PhD student at the Laboratory of Natural Products Chemistry, Graduate 
School of Pharmaceutical Sciences, Chiba University, under the supervision of Prof. M. 
Ishibashi, I continued the ongoing research works on search for bioactive natural products with 
TRAIL-resistance overcoming activity exploring natural resources as actinomycetes and 
medicinal plants. Although a number of natural products have been reported to show TRAIL-
resistance overcoming activity, still we continued to search for some active compounds. This is 
due to the fact that we may be able to isolate some better lead compounds in terms of potency 
and efficacy compared to the existing agents. In this report, I shall present the exploration of 
actinomycetes and the medicinal plants of Bangladesh to isolate bioactive compounds with 
TRAIL-resistance overcoming activity.   
 
January, 2010 Firoj Ahmed 
Chiba University 
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Chapter 1 
 
I: Assay Protocol 
 
Principle: TRAIL-resistance overcoming activity of the extracts and isolates was assessed by 
comparison of cell growth inhibitory activity in the presence and absence of TRAIL against 
TRAIL-resistant human gastric adenocarcinoma (AGS) cell lines. Cell growth inhibitory activity 
of the test samples was determined by Fluorometric Microculture Cytotoxicity Assay1 (FMCA) 
method using Fluorescein Diacetate (FDA) as a dye. FDA is a nonfluorescent compound which 
is converted to fluorescent compound after hydrolyzed by the enzyme esterases, produced by the 
viable cells. Thus, the fluorescence intensity is directly proportional to the number of viable cells, 
which is calculated as follows:  
 
 
  
 
 
 
 
 
 
 
 
 
Viability (%): 100 – Cell Growth Inhibitory Activity 
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Fig. 1-1 TRAIL-resistance overcoming activity of samples 
 
 
In the above chart (Figure 1-1), green bar represents the viability of the sample treated cells and 
the red bar represents the viability of combined treatment of sample and TRAIL treated cells. 
The viability difference of more than 25% between these two was considered as active sample. 
 
Method: At first AGS cells, suspended in RPMI1640 medium, are seeded on a black 96-well 
plate (6 × 103/well). After 24 h incubation at 37oC, media is removed and sample and/or TRAIL 
are added. Again after 24 h incubation, media is removed and 200 µl PBS containing FDA is 
added in each well, and incubated at 37oC for 1 h. Fluorescence of the each well is determined by 
a fluorometer.2-3 
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II: Screening of Actinomycetes Library 
 
MeOH extracts of actinomyecetes culture broths, collected from different areas of Japan were 
screened for TRAIL-resistance overcoming activity. About 23 strains were found active among 
the 120 tested strains. Activity of some selected strains is shown below: 
 
 
Fig.1-1 TRAIL-resistance overcoming activity of some actinomycetes extracts 
 
 
CKK105, CKK237, and CKK 190 were selected for bioassay guided separation 
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III: Screening of Plant extracts (Bangladesh) Library 
 
About 83 extracts of medicinal plants, collected from Bangladesh, were screened for TRAIL-
resistance overcoming activity, among which 25 were found active. Activity of some selected 
extracts is shown below: 
 
 
Fig. 1-2  TRAIL-resistance overcoming activity of some extracts of medicinal plants of Bangladesh 
(KKB01: Adiantum phillipense; KKB06: Hygrophila spinosa; KKB07 Mesua ferrea/ M. nagassarium; 
KKB09: Sida acuta; KKB16: Terminalia bellerica; KKB27: Sonneratia caseolaris;  KKB39: Amoora 
cucullata; KKB50: Urginea indica) 
 
KKB09 and KKB39 were selected for bioassay guided separation. 
[Among the extracts library, KKB12 - KKB83 were screened by Mr. Tomohiro Minakawa, and 
the activity charts are attached in Appendix-II.] 
µg/ml 
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Chapter 2 
 
 
Introduction 
 
Actinomycetes, also known as actinobacteria, are a potent and prolific source of bioactive 
compounds, including a wide array of anti-infective, antibacterial, antifungal, and antitumor 
agents.1-3 Due to its ability to produce diversified secondary metabolites, it has been explored 
extensively in search for bioactive natural products. In search for natural products with TRAIL-
resistance overcoming activity, we explored actinomycetes, collected in Japan.  
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A-1: Fermentation and separation of CKK105 
 
Fermentation: Spores of the strain growing on solid Waksman medium4 were inoculated into a 
1 L round bottom flask containing 100 mL liquid medium, and then incubated at 28 °C for 5 
days with reciprocal shaking at 200 rpm to produce seed culture.  The seed culture (10 mL) was 
then inoculated into each of 10 3 L flasks, each containing 500 mL of liquid Waksman medium, 
and incubated at 28 °C for 7 days with reciprocal shaking at 200 rpm to get 5 L fermentation 
broths. Following diagram (Figure 2-1) showed the fermentation process. The fermented culture 
broth underwent subsequent separation. 
 
 
 
Fig. 2-1 Cultivation and fermentation of CKK105. 
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Extraction and Isolation: Fermentation broths (5 L) thus obtained were centrifuged, and the 
supernatant was concentrated to 1 L and partitioned between EtOAc and BuOH. The EtOAc 
extract, obtained as active fraction (Figure 2-2), subjected to ODS flash column chromatography 
yielded 153 mg of novobiocin (3). The BuOH extract, subjected to ODS flash column 
chromatography afforded active fractions 1B and 1C. Fraction 1B (3 g) was subjected to silica 
gel column chromatography (CHCl3-MeOH, 3:1→0:1) followed by ODS HPLC (50% MeOH,  
develosil ODS HG-5, 10 × 250 mm, flow rate 1.5 mL/min) to yield compound 1. Fraction 1C 
(200 mg) was subjected to ODS HPLC (65% MeOH, develosil ODS HG-5, 10 × 250 mm, flow 
rate 1.2 mL/min) to yield compound 2 (3.5 mg, tR 20 min) (Figure 2-3). 
 
 
 
 
Fig. 2-2 Activity of fractions of CKK105, alone or in combination with TRAIL(100 ng/ml) against 
AGS cells;  MeOH (ME), EtOAc (EA), and BuOH (BU) extracts.  
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Fig. 2-3 Isolation scheme of CKK105 fermentation broths. 
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A-2: Structure elucidation of CKK105 isolates (1-3) 
 
Bioassay-guided fractionation of the fermentation broths of the soil actinomycetes, identified as 
Streptomyces sp. IFM 10937, led to the isolation of two new tyrosine derivatives 1 and 2 from its 
BuOH extract, and novobiocin (3) from an EtOAc extract (Figure 2-4).  
 
1 3
6
89
10 12
13
14
OH
(S)
HO
O
NHR
 
 
Fig. 2-4  Structures of compounds 1-3. 
 
Compound 1 was isolated as optically active, colorless solid and was assigned the molecular 
formula C16H21NO4 on the basis of (−)­HRFABMS, and 1H and 13C NMR spectroscopic data 
(Figure 2-5).  The IR spectrum showed a strong absorption band at 1651 cm−1, suggesting the 
presence of one or more carbonyl groups.  The 1H NMR spectrum (CD3OD) exhibited signals of 
four sp2 methines (δH 6.88, 6.86, 6.62, and 5.19), one aliphatic methine (δH 4.39), two 
sp3 methylenes [δH 3.23 (2H); 3.09 and 2.79], and three methyl singlets [δH 1.88, 1.71, and 1.69 
(each 3H)]. The 13C NMR (CD3OD) spectrum exhibited 16 signals, of which 10 resonated 
between δC 115.7 to 179.8. The other six included one aliphatic methine (δC 57.8), two aliphatic 
methylenes (δC 38.2 and 29.3), and three methyls (δC 25.9, 22.7, and 17.9).  Carbons with their 
attached protons were assigned by the HMQC experiment. The chemical shifts of the quaternary 
carbons represented two carbonyls (δC 179.8 and 172.7) and four sp2 carbons at δC 154.6, 132.6, 
1: R = COCH3 
2: R = H 
 
O O
O
H
N
OH
O
O
OH
O
MeO
OH
H2N O 3 
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130.2, and 128.9.  From HMBC and COSY correlations (Figure 2-6), and from their coupling 
constants, three methine signals at δH 6.88 (d, J = 2.0, 1H), 6.86 (dd, J = 8.3, 2.0, 1H), and 6.62 
(d, J = 8.3, 1H) with their corresponding carbons (δC 131.5, 128.4, and 115.7) were assigned to a 
1, 2, 4- trisubstituted benzene ring. This system was oxygenated at C-4, determined on the basis 
of HMBC correlations from both H-2 (δH 6.88) and H-6 (δH 6.86) to a carbon at δC 154.6. It was 
further supported by the proton signal of a phenolic hydroxy group at δH 9.00 in DMSO-d6. H-2 
and H-6 showed HMBC correlations to a carbon at δC 38.2 (C-7), to which the diastereotopic 
protons δH 2.79 (H-7a) and 3.09 (H-7b) were attached.  Both H-7a and H-7b showed HMBC 
correlations with the carbons at δC 130.2 (C-1), 131.5 (C-2), and 128.4 (C-6). These findings 
confirmed that C-7 was a benzylic carbon attached to C-1.  The COSY spectrum and 1H-1H 
coupling constants revealed that the diastereotopic protons H-7a [δH 2.79 (dd, J = 13.7, 8.5 Hz, 
1H)] and H-7b [δH 3.09 (dd, J = 13.7, 4.4 Hz, 1H)] were positioned next to the aliphatic methine 
proton H-8 [δH 4.39 (dd, J = 8.5, 4.4 Hz, 1H)] which was attached to the carbon at δC 57.8 (C-8). 
These characteristic data suggested that compound 1 was a derivative of the α-amino acid 
tyrosine.5 HMBC correlations from H-7a, H-7b and H-8 to a carboxylic acid carbonyl at δC 172.3 
provided further proof for this assignment.   From HMBC and COSY correlations, the methine 
signal at δH 5.19 (t-like, J = 7.4 Hz, 1H) attached to δC 124.3, the methylene signal at δH 3.23 (d, 
J = 7.1 Hz, 2H) attached to δC 29.3, and two methyl singlets at δH 1.71 and 1.69 with respective 
carbons at δC 25.9 and 17.9 were assigned to a dimethylallyl group. The allylic methylene 
protons H-10 (δH 3.23, 2H) attached to the carbon at δC 29.3 showed HMBC correlations with 
C-2, C-3, and C-4 suggesting its attachment to C-3 of the benzene ring. This assignment was 
further supported by the HMBC correlation of the allylic methine H-11 (δH 5.19) to C-3.  The 
methyl singlet at δH 1.88 (3H) showed HMBC correlation only with the carbonyl carbon at δ 
179.8 and was thus assigned to an acetyl moiety. Although no 2D NMR correlations were 
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observed between the acetyl moiety and the amino acid skeleton, the best possibility of its 
linkage was to the amino group of the substance forming an amide linkage (-NHCO-).  It was 
supported by the relatively lower field (δH 4.39) H-8 signal of 1, compared to that of 3-
chlorotyrosine where the same proton resonated at δH 3.37,6 and that of compound 2 resonated at 
δH 3.67 (vide infra). 
 
 
Fig. 2-5  1H and 13C NMR of  1.  
 
 
 
Fig. 2-6  COSY and HMBC correlations of 1. 
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Compound 2 was isolated as an optically active colorless solid and was assigned the molecular 
formula C14H19NO3 on the basis of (−)­HRFABMS, and 1H and 13C NMR spectroscopic data 
(Figure 2-7).  The IR spectrum showed a strong absorption band at 1606 cm−1 indicating the 
presence of a carbonyl group.  The 1H NMR spectrum (CD3OD) exhibited signals of four sp2 
methines (δH 6.99, 6.93, 6.71, and 5.32), one aliphatic methine (δH 3.67), two sp3 methylenes 
[δH 3.27 (2H); 3.20 and 2.83], and two methyls (δH 1.71, br s, 6H). The 13C NMR (CD3OD) 
spectrum exhibited 14 signals, of which nine resonated between δC 116.2 to 174.0. The 
remaining five carbons included one aliphatic methine (δC 57.8), two methylenes (δC 38.2 and 
29.3), and two methyls (δC 26.0 and 17.8). These data were similar to those of compound 1 
except for the absence of signals due to an acetyl moiety (carbonyl carbon at δC 179.8, a methyl 
singlet at δC 22.7 with its corresponding proton at δH 1.88 observed for 1) and an up-field shift 
of H-8 at δH 3.67 (dd, J = 9.0, 4.1 Hz, 1H).   It further supported the assignment of the acetyl 
moiety as attached to the amino group of 1, where the H-8 proton signal resonated at δH 4.39. 
Due to the absence of the acetyl moiety in compound 2, it conferred a free amino group which 
caused an up-field shift of H-8 proton at δH 3.67.5,6  
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Fig. 2-7  1H and 13C NMR of  2. 
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A-3: Determination of absolute configuration of compounds 1 and 2 
I. From CD data 
The absolute configuration of compounds 1 and 2 was first proposed by comparing their CD 
spectra with that of 3-chloro-L-tyrosine.7 The CD of 1 showed positive Cotton effects at λext 210 
nm (∆ε + 9.8) and 235 nm (∆ε + 3.3), 2 showed Cotton effects at λext 208 nm (∆ε + 6.7) and 234 
nm (∆ε + 1.4).  3-Chloro-L-tyrosine showed Cotton effects at λext 208 nm (∆ε + 8.3) and 232 nm 
(∆ε + 3.3). These observations suggested that the absolute configuration of compounds 1 and 2 
were same as L-tyrosine, and thus these compounds were assigned 8S configuration. 
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II. By Modified Marfey’s Method 
 
The absolute configuration of 2 was further confirmed by a modification of Marfey's method,8 
using D-FDLA (1-fluoro-2, 4-dinitrophenyl-5-D-leucinamide) and L-FDLA as derivatizing 
agents.9  In this method, the resolution between the L- and D-amino acid derivatives was due to 
the difference in their hydrophobicity, which was derived from the cis- or trans-type 
arrangement of two more hydrophobic substituents at both α-carbons of an amino acid and 
leucinamide.10  In the following figure the formation of cis and trans type arrangement are 
explained, considering L/D-valine as representative amino acid or amino compounds. The FDLA 
derivative of the cis (Z)-type arrangement interacts more strongly with ODS silica gel and has a 
longer retention time than that of the trans (E)- type arrangement.   
 
H
O N
N
N O
HN
O O
HHHOOC
(H3C)2HC
L-Valine
L-FDLA
D-FDLA
D-valine
L-FDLA
D-FDLA
D-D
RT
Hydrophobic groups are in trans-type arrangement
H
O N
N
N O
HN
O O
HHHOOC
(H3C)2HC
cis-type arrangement
H
O N
N
N O
HN
O O
H
CH2CH(CH3)2
H
(H3C)2HC
trans-type arrangement
HOOC
L-L
L-D/D-L
Hydrophobic groups
CH2CH(CH3)2
CONH2
CONH2
CH2CH(CH3)2
CONH2
 
 
Fig 2-8 Formation of cis and trans-type arrangement after D/L-FDLA derivatization of valine. 
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Generally, L-FDLA derivatives of L-amino acids (L-L type) confer trans-type arrangements and 
the D-FDLA derivatives (D-L type) confer cis-type arrangements.   Therefore, the L-L type 
complex is eluted earlier than the D-L type (Figure 2-8).   
 
When 2 was derivatized with L- and D-FDLA,  respectively, the L-FDLA derivative (L-2) was 
eluted earlier (61.72 min) than its D-FDLA derivative, D-2 (66.12 min) (Figure 2-9). These 
results indicated that L-2 had a trans-type arrangement and D-2 had a cis-type arrangement. 
These results suggested the configuration of tyrosine in 2 was L,11 which was consistent with the 
CD comparison data, and thus its absolute configuration was confirmed as 8S.  
 
 
 
Fig 2-9  D/L-FDLA derivatization of 2. 
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Compound 3 was isolated as a yellowish solid, and were determined as novobiocin, by 
comparing the 1H and 13C NMR data with that of literature.12 
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A-3: Activity of CKK105 isolates (1-3) 
 
The isolated compounds (1–3) were evaluated for their activity in overcoming TRAIL-resistance 
in AGS cells. Recently, this cell line has been widely used as a model system for evaluating 
cancer cell apoptosis,13 and is reported to be refractory to apoptosis induction by TRAIL.14  To 
assess the effects of 1-3, TRAIL, or their combined treatment on cell viability, AGS cells were 
treated with the indicated agents and subjected to FMCA.15  As shown in Figure 2-10, treatment 
with 100 ng/mL TRAIL for 24 h resulted in only a slight decrease in cell viability (92 ± 4%), 
which was similar to the effects of 1 and 3 alone. Luteolin, used as positive control, produced 
about 70% more inhibition along with TRAIL than the TRAIL alone. Treating cells with 100 
ng/mL TRAIL and 75 or 150 µM of 1 reduced cell viability to 77 ± 7% and 67 ± 5% of control 
levels (p < 0.01), respectively, which was 15 and 25% more than the TRAIL alone, suggesting a 
possible synergism between the two agents. Combined treatment with TRAIL and 2 did not 
produce any significant reduction in the cell viability suggesting its inactivity in overcoming 
TRAIL resistance. On the other hand, treatment with TRAIL and 37.5  or 75 µM of 3 reduced 
cell viability to 72 ± 6% and 63 ± 5% of controls (p < 0.01), respectively, which was 20 and 29% 
more than the TRAIL alone. These results tend to suggest its possible synergistic activity in 
combination with TRAIL against AGS cells.  
 
Resistance of cancer cells toward TRAIL may occur at different points in the TRAIL-induced 
apoptotic pathways. Understanding the mechanisms of such resistance and developing strategies 
to overcome it are important for the successful use of TRAIL in cancer therapy.16  Combined 
treatment of TRAIL and chemotherapeutic agents including some natural products can overcome 
such resistance, and sensitize TRAIL-resistant cells to enhance the therapeutic potential of 
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TRAIL against the cancer cells. Therefore, a natural product producing synergistic activity with 
TRAIL would be a new tool for cancer therapy.17   
 
 
 
 
Fig. 2-10 Effect of the isolated compounds 1-3, Luteolin (positive control: Lut) and TRAIL treatment, 
alone and in combination, on the viability of AGS cells. Cells were seeded in a 96-well culture plate (6 × 
103 cells per well) for 24 h and then treated with indicated concentrations (µM) of the isolates and/or 
TRAIL for 24 h. Cell viability was determined by Fluorometric Microculture Cytotoxicity Assay 
(FMCA). The bar represents the means (n = 3 ± SD). Significance was determined by Student’s t-test p < 
0.01 (**) vs. control (Con) 
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In this study, 1 along with TRAIL showed synergistic activity against AGS cells, relatively at a 
higher concentration of 150 µM. A cyclic peptide, isolated from the mold Aspergillus flavipes, 
containing 3-prenyl-β-hydroxytyrosine, a structurally related compound to 1, has been reported 
as a competitive antagonist of NK1 and NK2 receptors.18 No other structurally similar 
compounds to 1 are, however, reported so far. Compound 3 (novobiocin) along with TRAIL, 
produced synergistic activity against AGS cells at concentrations of 37.5 and 75 µM. Novobiocin, 
a topoisomerase II inhibitor, has been reported to potentiate the cytotoxicity of some 
chemotherapeutic agents such as etoposide and teniposide,19  epirubicin and doxorubicin,20 and 
cis-platin.21  Here, we report for the first time, the synergistic activity of 3 in sensitizing TRAIL-
resistant AGS cells to TRAIL. 
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B-1: Fermentation and separation of CKK237  
 
Fermentation, and isolation process were same as described in section A-1.  Following diagram 
represents the total fermentation and isolation scheme of CKK237 (Figure 2-11). 
 
EA (EtOAc extract from supernatant)
635 mg
Aqueous layer
( EtOAc 800 ml x 3)
(BuOH 700 ml x 3)
BU (BuOH extarct), 6 g Aq. ext.
Concentrated to 0.8 L,
partitioned successively
A loopful inoculated into 100 ml liquid waksman medium in a 1 L 
round bottom flask, incubated for 4 d at 28-30oC with shaking
Centrifuged at 4x103 rpm for 10 min,
CKK237 Subculture
10 ml culture transferred into 500 ml liquid waksman medium 
in  a 3 L flask, Incubated for 7 d at 28-30oC with shaking
Extracted with  MeOH for 5 d, 
centrifuged at 4x103 rpm
Supernatent (5L) Residue/mycelium cake
Supernatent 1.5L
MEA  (EtOAc ext.) 
300 mg
Aqueous layer
( EtOAc 300 ml x 3)
( n- BuOH 200 ml x 3)
MBU (BuOH extract), 400 mg Aqueous extract
Evaporated ( 2.7 g), dissolved in 10% 
MeOH, partitioned successively
Silica gel CC # 1,  PSQ 100-B,
(35 x 4.5) cm,  CHCl3/MeOH
1A 
36.3
1B 
66.7
1C 
160.2
1D 
119.4
1E 
29.5
1F
38.7
1G
26.2
1H
6.2
9:1 9:1 7:1 7:1 7:1 7:1
1I
6.1
1J
2.7
1K
7.8(mg)
1L
6.4
7:1 5:1 5:1 3:1 1:1 MeOH
ODS CC # 3,  (25 x 2) cm  
MeOH/H2O
3A 
10.6
3B 
12.4
3C 
82.5
3D 
5.9
3E 
3.8
3F
3.0
3G
1.7
3H
1.5
1:4 1:4 1:4 1:4 1:4 2:3
(mg)
2:3 1:1
3I
2.1
3J
17.1
2:1 MeOH
ODS HPLC # 5, Inertsil ODS 3 
(250 x 10) mm; MeOH/H2O: 1/2
5A, 0.7 mg      
4
5B, 1 mg
6
5C, 14.5 mg 
5
5D, 16 mg 
7
22 min 24 min 26 min 38 min
 
 
 
Fig. 2-11 Fermentation and isolation scheme of CKK237 
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B-2: Structure determination of the CKK237 isolates 
 
 
Bioassay-guided fractionation of the fermentation broths of the soil actinomycetes CKK237, led 
to the isolation of four known diketopiperazines (4-7) from its EtOAc extract. Structures of 
compounds 4-7 were determined by comparing the NMR spectral data (Appendix-I) with that of 
literature. Compound 4 was isolated as colorless solid, and was determined as cyclo (D-prolinyl-
L-valine).22 Compound 5 was isolated as colorless solid, and was determined as cyclo (D-cis-
hydroxyprolinyl-L-leucine).23 Compound 6 was isolated as colorless solid, and was determined 
as cyclo (D-cis-hydroxyprolinyl-L-isoleucine).24 Compound 7 was isolated as colorless solid, and 
was determined as cyclo (L-trans-hydroxyprolinyl-L-phenylalanine)25 (Figure 2-12). 
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Fig.2-12  Structures of compounds 4-7. 
 
4: Cyclo (D-Pro-L-Val) 
 
5: Cyclo (D-cis-Hyp-L-Leu) 
 
6: Cyclo (D-cis-Hyp-L-Ile) 
 
7: Cyclo (L-Hyp-L-Phe) 
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B-3: Activity of the CKK237 isolates 
 
The isolated compounds (4–7) were evaluated for their activity in overcoming TRAIL resistance 
in AGS cells. As shown in Figure 2-13, among the isolates, compounds 5 and 7 showed mild 
activity. Combined treatment with TRAIL (100 ng/mL) and compounds 5 and 7 produced 22% 
more inhibition than the agents alone at 50 and 25 µM, respectively.  Compounds 4 and 6 did not 
produce any significant reduction in the cell viability suggesting its inactivity in overcoming 
TRAIL resistance.  
 
 
 
 
Fig. 2-13 Effect of the isolated compounds 4-7, and TRAIL treatment, alone and in combination, on the 
viability of AGS cells. Cells were seeded in a 96-well culture plate (6 × 103 cells per well) for 24 h and 
then treated with indicated concentrations (µM) of the isolates and/or TRAIL for 24 h. Cell viability was 
determined by Fluorometric Microculture Cytotoxicity Assay (FMCA). 
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C-1: Fermentation and separation of CKK190  
 
Bioassay-guided fractionation of CKK190 broths, led to the isolation of compounds (8-11) from 
its EtOAc extract. Following figure represents the fermentation and isolation scheme for the 
separation of CKK190 (Figure 2-14). 
 
 
EA (EtOAc extract from supernatant)
980 mg
Aqueous layer
(EtOAc 600 ml x 3)
(BuOH 400 ml x 3)
BU (n-BuOH extarct from supernatant)
6.1 g
Aqueous extract
Concentrated to 0.6 L,
partitioned successively
A loopful inoculated into 100 ml liquid waksman medium in 
a 1 L round bottomed flask, incubated for 4 d at 28-30oC
Centrifuged at 4x103 rpm for 10 min,
10 ml culture transferred into 500 ml liquid waksman medium 
in  a 3 L kabu flask, Incubated for 5 d at 28-30oC
Supernatent (5L) Residue/mycelium cake
Stock Culture
A loopful spreaded over solid waksman medium in a 
petridish, Incubated for 72 h at 28-30oC
Subculture
ODS Flash CC # 1, 
(52 x 2.5) cm, MeOH/H2O
1A 
310
1B 
111
1C 
158
1D 
44
1E 
17.9
1F
6.8
1G**
13.5
1H
8.7
1:2 1:2 1:2 2:3 1:1 1:1
1I
2.3
1J**
15.9
1K
53.6 (mg)
3:2 2:1 2:1 2:1 3:1 MeOH
2A 
12.4
2B 
23
2C 
7
2D* 
2.3
2E 
1.2
2F
3.1
2G
0.6
2H
0.5
2:3 2:3 2:3 2:3 2:3 1:1
(mg)
1:1 1:1
2I
1.5
Silica gel CC # 2, PSQ 100B 
(25 x 2) cm,  MeOH/H2O
MeOH
2J
3.4
2K
3.0
3B 
10
3C 
0.4
3D 
0.2
Sephadex LH20 CC # 3,   
(50 x 1.8) cm,  MeOH
4A  
2
4B 
8
4C 
0.9(mg)
Sephadex LH20 CC # 4   
(50 x 1.8) cm,  MeOH
4D
Soluble 
2E1
Insoluble
10,  0.7 mg
Dissolved in CHCl3
7A* 7B* 7C, 2.1 mg
11: Cyclo-Pro-Phe
7D
Silica gel PSQ 100B CC # 7  
(30 x 2) cm,  CHCl3/MeOH8A 
3
8B
110
8C
16
8D
1.5(mg)
8E
2.8
ODS Flash CC # 8  (58 x 2.7) cm  
CHCl3/MeOH: 2/3
9A 
0.2
9B
0.4
9C, 2.1 mg
8: Cycloheximide
9D, 2.9 mg
9: Isocycloheximide
(mg)
9E
ODS HPLC # 9
Develosil ODS HG-5, 10x250 mm
50% MeOH, RI detector
14 min 19 min 28 min 35 min
MeOH added
 
 
 
Fig. 2-14 Fermentation and isolation scheme of CKK237 
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C-2: Structure determination of the CKK190 isolates 
 
 
Structure of compounds 8-11 were determined by comparing the NMR spectral data (Appendix-
I) with that of literature. Compounds 8 and 9 were determined as cycloheximide and 
isocycloheximide, respectively.26 Compound 10 was isolated as colorless solid, and was 
determined as cyclo (L-phenylalanyl-L-tyrosine).27 Compound 11 was isolated as colorless solid, 
and was determined as cyclo (D-cis-hydroxyprolinyl-L-isoleucine)28 (Figure 2-15). 
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Fig. 2-15  Structures of compounds 8-11. 
 
11: Cyclo (L-Pro-L-Phe) 
 
10: Cyclo (L-Phe-L-Tyr) 
 
8: Cycloheximide 
 
9: Isocycloheximide 
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C-3: Activity of CKK190 isolates 
 
The isolated compounds (8–11) were evaluated for their activity in overcoming TRAIL 
resistance in AGS cells. As shown in Figure 2-16, compound 10 showed moderate activity, 
whether 8 and 11 showed strong activity in overcoming TRAIL resistance. Combined treatment 
with TRAIL (100 ng/mL) and compound 10 produced 26% more inhibition than the agent alone 
at 30 µM.  Combined treatment with TRAIL (100 ng/mL) and compounds 8 and 11 produced 37 
and 29% more inhibition than the agents alone at 2.5 and 75 µM, respectively.  
 
 
 
Fig. 2-16 Effect of the isolated compounds 8-11, and TRAIL treatment, alone and in combination, on the 
viability of AGS cells. Cells were seeded in a 96-well culture plate (6 × 103 cells per well) for 24 h and 
then treated with indicated concentrations (µM) of the isolates and/or TRAIL for 24 h. Cell viability was 
determined by Fluorometric Microculture Cytotoxicity Assay (FMCA). 
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Chapter 3 
 
A-1: Separation of Vallaris solanaceae 
 
 
Vallaris solanaceae Kuntze (syn.: Vallaris heynei) (Apocynaceae), locally known as ‘agarmoni’ 
grows in Bangladesh and other Southeast Asian countries.  It is a creeper with fragrant white 
flowers, traditionally used against ring worms and skin infections.1 Previous chemical 
investigation of its leaves reported to isolate β-sitosterol, β-amyrin, ursolic acid,2 and 
triterpenes;3 vallaroside, solanoside, vallarosolanoside, and acoshimperosid P.4-5  
 
Extraction and Isolation.  
MeOH extract of V. solanaceae (70 g) chromatographed over Diaion HP-20 to exclude the 
chlorophyll content. The Chlorophyll free fraction (35 g) was then partitioned between hexane, 
EtOAc, and n-BuOH.   
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EtOAc extract (2.64 g) was subjected to Silica gel PSQ100B CC to afford six fractions, 2A-2F.  
Fraction 2B (515 mg) was chromatographed over silica gel PSQ100B to afford five fractions, 
3A- 3E. Compound 12 (4.5 mg) was isolated from fraction 3D (230 mg) after performing ODS 
HPLC. Fraction 2C (260 mg) was subjected to ODS flash column chromatography to get three 
fractions, 5A-5C. Compound 13 (2.8 mg) was isolated from fraction 4B (98 mg) after Sephadex 
LH20 CC, followed by Silica gel PSQ100B CC. Fraction 2E (310 mg) was subjected to Silica gel 
PSQ100B CC to afford fractions 5A-5C.  Fraction 5B (48 mg) underwent ODS flash column 
chromatography to yield compound 14 (2.6 mg) (Figure 3-1).  
 
 
 
 
 
Fig. 3-1 Isolation Scheme of V. solanaceae 
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A-2: Structure elucidation of 12-14 
 
The MeOH extract of V. solanaceae was partitioned between hexane, EtOAc, and BuOH, 
followed by repeated column chromatography and preparative HPLC to afford compounds 12-14.  
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Fig. 3-2 Structures of 12-14 
 
 
Compound 12 was isolated as optically active, colorless solid, and was assigned the molecular 
formula C32H46O9 on the basis of HRFABMS (m/z 597.3008 [M+Na]+, ∆ mmu − 3.2) and 1H 
and 13C NMR spectroscopic data. The IR spectrum showed the presence of an α, β-unsaturated 
lactone (1740 cm−1), a strong hydroxyl absorption (3450 cm−1), and carbon-carbon double 
bond(s) (1620 cm−1). In the 1H NMR spectrum, two double doublets (each 1H) at δ 5.14 (J = 
16.5 and 1.6 Hz) and 5.00 (J = 16.5 and 1.6 Hz) were attributed to H-21a and H-21b, and a 1H 
broad singlet at δ 6.00 was assigned to H-22, whereas, two methyl singlets at δ 1.27 and 1.00 
were attributed to H3-18 and H3-19, respectively. The presence of an α, β-unsaturated γ-lactone 
with further conjugation was also evident from its UV absorption maxima at 270 nm.6 The 
12: R = COCH3 
13: R = H 
 
14 
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double bond was placed at C-16/17 position, both on the basis of HMBC correlation from H-16 
(δ 6.25, t, J = 2.7 Hz) to C-13 (δ 53.4), C-14(δ 86.7), and C-20 (δ 161.9), and considering that 
the UV maximum was at 270 nm. This assignment was further confirmed from two double 
doublets at δ 2.77 (dd, J = 18.3 and 3.3 Hz, H-15a) and 2.30 (dd, J = 18.3 and 3.3 Hz, H-15b). A 
broad singlet at δ 3.96 was assigned to the carbinylic proton H-3. The 1H and 13C NMR data of 
12, thus revealed an identical aglycone to that of 16-anhydrogitoxigenin.7  
 
In addition, the 1H and 13C NMR data (Figure 3-3) indicated the presence of one molecule of 
sugar because of an anomeric proton at δ 4.81 for H-1’ (d, J = 1.7 Hz) connected to the anomeric 
carbon at δ 97.3 in the HMQC spectrum. The INEPT data for J C1’- H1’ was observed to be 170 
Hz indicating the α-linkage of the sugar.8 The connectivity of all carbons with their 
corresponding protons of the sugar moiety was assigned by the HMBC and COSY spectrum 
(Figure 2a), and from the coupling constants. H-2’ proton, connected to C-2’(δ 70.3), showed a 
double doublet at δ 5.18 (J = 3.4 and 1.7 Hz); H-3’, connected to C-3’(δ 80.7), appeared as a 1H 
double doublet at δ 3.46 (J = 9.5 and 3.4 Hz); H-4’, connected to C-4’(δ 73.2), appeared as a 1H 
triplet at δ 3.35 (J = 9.5 Hz); H-5’, connected to C-5’(δ 70.0), appeared as a doublet of quartet at 
δ 3.70 (J = 9.5 and 6.4 Hz) whereas H3-6’, connected to C-6’(δ 18.0), resonated as a 3H doublet 
at δ 1.23 (J = 6.4 Hz). The OMe group (δC 58.0; δH 3.40, s) was assigned to be linked to C-3’ on 
the basis of the HMBC correlation from the methoxy protons at δ 3.40 to C-3’ at δ 80.7. From 
these data the structure of the sugar was determined as α-acofriose (3-O-methyl-α-rhamnose).9 
Besides, presence of an acetyl moiety was confirmed from the HMBC correlation from the 
methyl singlet at δ 2.07 to the carbonyl carbon at δ 172.0. The HMBC correlation from H-2’ to 
this carbonyl carbon indicated that the acetyl group was connected at C-2’ of acofriose. Thus, the 
sugar was characterized as 2’-O-acetyl-α-acofriose.  
44 
 
 
 
Fig. 3-3 1H and 13C NMR of 12 
 
 
Based on the identical 1H and 13C NMR data, aglycone of 12 was proposed to confer the same 
configuration as that of 16-anhydrogitoxigenin (3β-O, 5β, 8β, 9α, 14β-OH, 10β-CH3, and 13β- 
CH3) and was further confirmed by differential NOE experiments (Figure 3-4b). Irradiation of 
both H3-18 (δ 1.27) and H3-19 (δ 1.00) showed NOEs in H-8 (δ 1.76, m), and irradiation of H3-
19 (δ 1.00) showed NOEs in H-5 (δ 1.63, m) and H-8 indicating their same orientation. The 
upfield chemical shift of C-9 (δ 37.6) was due to the steric interaction between its axial hydrogen 
and C(14) - C(15) bond. Due to the equatorial β-effect of the C-14β hydroxyl group, C-8 was 
resonated at a relatively lower field at δ 42.1.10 Thus, compound 12 was assigned the structure 
3β-O- (2’-O-acetyl-α-acofriosyl)-16-anhydrogitoxigenin.  
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Fig. 3-4 (a) COSY (bold lines) and key HMBC (arrows) correlations of 12; (b)  Selected NOE 
experiments of 12 
 
 
 
Compound 13, a cardenolide glycoside, was isolated as optically active,  colorless solid,  and 
was assigned the molecular formula C30H44O8 on the basis of FABMS (m/z 571 [M+K]+), 1H 
and 13C NMR spectroscopic data. These data were similar to those of compound 12 except for 
the absence of signals due to a 2’-O-acetyl moiety (carbonyl carbon at δC 172.0, a methyl singlet 
at δC 20.8 with its corresponding proton at δH 2.07 observed for 12) and an up-field shift of H-
2’at δH 4.02 (m) compared to the H-2’ (δ 5.18, J = 3.4, 1.7 Hz) of 12.  Thus, 13 was identified as 
3β-O-(α-acofriosyl)-16-anhydrogitoxigenin, which was formerly reported as 16-desacetyl-16-
anhydroacoshimperosid P by Kaufmann.5 Here, we report, for the first time the 1H and 13C NMR 
spectroscopic data of this compound (Appendix-I).  
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 Compound 14 was isolated as optically active, colorless oil, and was assigned the molecular 
formula C25H30O13 on the basis of HRFABMS (m/z 561.1593 [M+Na]+, ∆ mmu +0.9), and 1H 
and 13C NMR spectroscopic data (Figure 3-5). The 1H NMR spectrum showed three aromatic 
protons as two double doublets at δ 6.65 and 6.55, and a triplet at δ 7.24, along with five further 
aromatic protons in the 7.55–7.30 ppm range. Besides, three singlets at δ 5.43 and 3.51, two 
anomeric protons at δ 5.08 (d, J=7.2 Hz) and δ 5.37 (d, J=2.0 Hz), three multiplets at δ 3.88, 3.82 
and 3.66, one triplet at δ 3.56, and five overlapping protons in the δ 3.45–3.33 ppm range were 
also present in the spectrum. The 13C NMR exhibited 23 signals, including one carbonyl carbon 
at δ 170.1. Protons along with their respective carbons were assigned by HMQC data. On the 
basis of HMQC and HMBC experiments the structure of aglycon was determined as benzyl 2, 6-
dihydroxybenzoate which was previously reported as verimol K.11 Accordingly, enzymatic 
hydrolysis with β-glucosidase conferred verimol K.12 In addition, the presence of two sugar 
moieties was also evident from the 1H and 13C NMR data. The anomeric proton resonated at δ 
5.08 (d, J = 7.2 Hz) with its corresponding carbon at δ 100.6. Additional proton signals at δ 3.56 
(m, 2H), overlapping protons in the δ 3.45–3.33 ppm range, and one methylene signal at δ 3.82 
and 3.66, along with five carbon signals at δ 78.2, 78.0, 71.2, 79.9, and 62.5 implied that one of 
the sugars was a glucose. The orientation of anomeric proton for glucose (δ 5.08, d, J = 7.2 Hz) 
was deduced as β.13 The position of attachment of the disaccharide moiety was established by 
HMBC correlation between H-1’’ (δ 5.08, d, J = 7.2 Hz) and C-3 (δ 157.9).  The remaining 
five 13C NMR signals at δ 111.2, 78.1, 80.4, 75.2, and 65.7 could be assigned to the carbons of 
another sugar, apiose14 from the HMBC and COSY correlation (Figure 3-6). The orientation of 
anomeric proton (δ 5.37, d, J = 2.0 Hz) for apiose was deduced as β, from its smaller coupling 
constant (J=2.0 Hz)15 compared to that for α (J = 4.5 Hz).13  
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Fig. 3-5 1H and 13C NMR of 14 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
48 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3-6 COSY (bold lines) and key HMBC (arrows) correlations of 14. 
 
 
The apiofuranosyl terminal sugar was shown to be linked to glucose through a (1’’’    2’’) bond 
on the basis of HMBC correlation observed from H-1’’’ proton of apiose to the C-2’ of glucose 
at δ 78.2 together with the comparison of the 13C NMR data of 14 with that of benzyl 2-O-β-D-
glucopyranosyl-2, 6-dihydroxybenzoate12 which revealed that C-2’’ signal was shifted to 
downfield by 3.0 ppm, whereas C-1’’ appeared upfield by 2.5 ppm in 14.  
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Identification of sugars in 14 was confirmed as glucose and apiose by comparing the Rf values of 
the authentic sugars on TLC after enzymatic hydrolysis with β-glucosidase followed by acid 
hydrolysis (Figure 3-7). As β-glucosidase selectively catalyzes the hydrolysis of β-D-glucosides, 
the D-configuration was assigned for glucose. Thus the structure of 3 was determined as benzyl 
2-O- β-apiofuranosyl (1     2) -β-D-glucopyranosyl-2, 6-dihydroxy-benzoate.   
 
 
 
Fig. 3-7 Hydrolysis of 14 
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A-3: Activity of the isolates (12-14) 
 
The isolated compounds (12–14) were also evaluated for their activity in overcoming TRAIL-
resistance in AGS cells. To assess the effects of 12-14, TRAIL, or their combined treatment on 
cell viability, AGS cells were treated with the indicated agents and subjected to FMCA. As 
shown in Figure 3-8, treatment with 100 ng/mL TRAIL for 24 h resulted in only a slight 
decrease in cell viability (89 ± 3%). Luteolin, used as a positive control, produced about 50% 
more inhibition along with TRAIL than the agent alone. Compound 12 at 5, 10, and 20 µM 
reduced cell viability to 75 ± 6.0%, 48 ± 3.0%, and 35 ± 2.5% of control levels, whereas, 
combined treatment along with 100 ng/mL TRAIL further reduced the cell viability to 43 ± 6.0%, 
11 ± 2.0%, and 4 ± 0.2% of control levels (p< 0.01), respectively, which was 32, 37, and 31% 
more than the agent alone. These results suggested a possible synergism between 1 and TRAIL.  
 
 
 
Fig. 3-8 Effect of compound 12, Luteolin (positive control: Lut) and TRAIL treatment, alone and in combination, on 
the viability of AGS cells. The bar represents the means (n = 3 ± SD). Significance was determined by Student’s t-
test p < 0.01 (**) vs. control (Con). 
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From the results it was evident that, 12 abrogated TRAIL-resistance of about 32% at 5 µM 
without any remarkable cytotoxicity. Compounds 13 and 14, however, did not produce any 
synergistic activity against AGS cell lines.  
 
It has been reported that some cardiac glycosides are proved to be potent cytotoxic agents against 
many cancer cell lines.16 For example, 7, 8-dehydrocerberin, isolated from Cerbera manghas, 
showed potent cytotoxic activity against KB (oral human epidermoid carcinoma), BC (human 
breast cancer), and NCI-H187 (human small cells lung cancer) cell lines.17 Some cardiac 
glycosides, for example, digoxin, digitoxin, oleandrin, lanatoside C, oubain, and bufalin are 
reported to sensitize TRAIL-resistant Calu1 (lung cancer) cells to Apo2L/TRAIL-induced 
apoptosis.18 
 
Although, compound 13 was structurally similar to 12, except for the absence of an acetyl 
moiety at C-2’ of 12. But it was devoid of TRAIL-resistance-overcoming activity. Thus, the 
presence of an acetyl group at C-2’ in compound 12, may have contributed to its strong TRAIL-
resistance overcoming activity in AGS cells. 
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B-1: Bioassay guided separation of Sida acuta  
 
 
Sida acuta Burm. (Malvaceae), locally known as ‘Bon methi’, ‘Berela’, etc., is a shrub collected 
from Dhaka, Bangladesh. It is distributed in all areas of Bangladesh, and other tropical countries. 
Its leaves are traditionally used as diuretic, demulscent, and in gonorrhea, rheumatic fever, and 
chronic dysentery; roots are used as tonic, diaphoretic and antipyretic, and used in CNS and 
urinary diseases.19 It was reported for antiplasmodial, antimicrobial, analgesic, free radical 
scavenging, and apoptosis inducing activities. Previously isolated constituents include alkaloids, 
tocoferols and triterpenoids, sterols,  poly phenols, and glycosides.20 
 
 
 
 
 
 
 
 
 
 
 
 
Extraction and Isolation: MeOH extract of S. acuta whole plants (9.7 g) was chromatographed 
over Diaion HP-20 (4.5 × 35 cm; particle size 250-850 µm) to exclude the chlorophyll content. 
The chlorophyll free fraction (8.1 g) was then suspended in 10% aq. MeOH (400 mL) and 
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partitioned between hexane, EtOAc, and BuOH. BuOH extract (2.7 g) was subjected to Silica gel 
PSQ100B Column chromatography using EtOAc-MeOH as solvent system with increasing 
polarity to afford four fractions, 2A-2D. Fraction 2B (420 mg) was chromatographed over silica 
gel PSQ100B using CHCl3-MeOH solvent system followed by ODS flash column 
chromatography and Sephadex LH20 column chromatography to get compound 15. EtOAc 
extract (1.9 g) was subjected to Silica gel PSQ100B Column chromatography to afford four  
fractions, 3A-3D. Fraction 3B (242 mg) was recrystallized to  get  compound 17 (40 mg). 
Fraction 3C (831 mg) was chromatographed over silica gel PSQ100B (2.5 × 45 cm) using 
EtOAc-MeOH solvent system to get compound 15 (85 mg) and 16 (332 mg) (Figure 3-9). 
 
 
 
 
 
Fig. 3-9 Isolation scheme of S. acuta 
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B-2: Structure elucidation of 15-17 
 
From the MeOH extract of whole plants of Sida acuta, three known compounds 15-17 were 
isolated. Structures of the compounds were determined by comparing their NMR data  to that 
literature (Appendix-I). 15 was an alkaloid, known as cryptolepine,21 first isolated from the roots 
of Cryptolepis triangularis. Compounds16 and 17 were determined as kaempferol glycosides, 
known as kampferol-3-O-α-L-rhamnopyranosyl-β-D-glucopyranoside22 and kampferol-3-O-β-D-
glucopyranoside,23  respectively (Figure 3-10). 
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Fig. 3-10 Structures of compounds 15-17. 
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B-3: Activity of the isolates 
 
I. TRAIL-resistance overcoming activity 
 
The isolated compounds (15–17) were evaluated for their activity in overcoming TRAIL 
resistance in AGS cells. As shown in Figure 3-11, compound 15 showed strong activity in 
overcoming TRAIL resistance. Combined treatment with TRAIL (100 ng/mL) and 15 produced 
31, 50, and 31% more inhibition than the agent alone at 1.25, 2.5, and 5 µM, respectively. 
Cryptolepine, reported as a candidate antitumor agent,24,25 exhibits potent cytotoxic activity 
against a wide variety of cancer cells, including human leukemia HL-60 cells.26 It induced cell 
cycle arrest and apoptosis by activating mitochondrial release of cytochrome c. Here, we found 
for the first time, its TRAIL-resistance overcoming activity against AGS cells. 
  
 
[Fig. 3-11 Effect of compound 15-17, luteolin (positive control: Lut) and TRAIL treatment, alone and in 
combination, on the viability of AGS cells. Cells were seeded in a 96-well culture plate (6 × 103 cells per well) for 
24 h and then treated with indicated concentrations (µM) of the compounds and/or TRAIL for 24 h. Cell viability 
was determined by Fluorometric Microculture Cytotoxicity Assay (FMCA). The bar represents the means (n = 3 ± 
SD). Significance was determined by Student’s t-test p < 0.01 (**) vs. control (Con). 
µM 
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II. Effect of compound 15 on TRAIL-mediated apoptosis in AGS cells 
 
It was found that the treatment of AGS cells with TRAIL (100 ng/ml) along with 15 (1.25, 2.5, 
and 5 µM) for 24 h resulted in 30, 50, and 31% more inhibition compared to 15 alone, which  
suggested a possible synergism between the two agents. To ascertain whether the decrease in cell 
viability was caused by apoptotic cell death, we checked the treated cells displaying apoptotic 
morphology by Hoechst staining. After 24 h of treatment, cells were stained with Hoechst33342 
reagent, and observed under microscope. We observed apoptotic nuclei with condensed 
chromatins stained more brightly in the treated cells than the normal cells. (Figure 3-12)  
 
 
 
Fig. 3-12 Effect of 15 and TRAIL treatment, alone and in combination, on apoptosis of human gastric 
adenocarcinoma cells. AGS cells were grown on cell culture dishes and treated as described in 
'Experimental' and apoptosis was detected by Hoechst 33342 stain. Representative photomicrographs 
from each treatment group showing induction of apoptosis (bright fluorescence).  
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III. Effect of compound 15 on Caspase-3/7 activity in AGS cells 
 
Caspase-3/7 are known as effector caspases, and after activated by the initiator caspases 
(Caspase-8/9), it induce apoptosis. During our attempt in investigating the molecular 
mechanisms underlying the apoptosis produced by compound 15, we also checked the caspase-
3/7 activity using caspase-3/7 assay kit (Promega) after 12 h of treatment.  We observed that the 
treatment of AGS cells with 15 in combination with TRAIL (100 ng/ml), increased caspase 3/7 
activity 2.3-fold compared with the control after 12 h (Figure 3-13).  
 
 
 
 
 
 
 
Fig. 3-13 Effect of combined treatment of 15 and TRAIL, on caspase-3/7 activity in human gastric 
adenocarcinoma cells. Values on top of the columns represent relative fold-induction compared to 
control considered as 1. Significance was determined by Student’s t-test (**, p< 0.01; *, p< 0.01) vs. 
control (Con). 
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IV.  DR5 promoter activity of compound 15  
TRAIL-mediated apoptotic pathway begins with the binding of TRAIL to the death receptors 
DR4/DR5,27 and for this, we checked DR5 promoter activity of 15 in DLD-1/Sac cells, stably 
transfected with DR5 promoter-luciferase reporter plasmids, pDR5/SacI with luciferase gene 
after 24 h of treatment.28 As shown in Figure 3-14, compound 15 did not show DR5 promoter 
activity, and tends to suggest that other pathways may be involved for its activity.  
 
 
 
Fig. 3-14 DR5 promoter  activity using DLD-1/SacI cells (Tested by Mr. Nakazawa) 
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C-1: Bioassay guided separation of A. cucullata  
 
Amoora cucullata Roxb. (syn.: Aglaia cucullata Roxb.) (Meliaceae) is a long tree, grown in 
coastal forests of Bengal, Burma, Malay peninsula, Andamans, and Borneo. It was collected 
from the Sundarbans Mangrove Forests, Bangladesh where it is known ‘Amoor’, ‘Latmi’ and 
‘Natmi’ among the local people. Its leaves are traditionally used in the treatment of 
inflammation;29 Juice of the leaves is antibacterial and extensively used for the treatment of 
dysentery, skin diseases and in cardiac diseases.30 Crude MeOH extracts of leaves were reported 
to show anti-inflammatory, antinociceptive, diuretic, and CNS depressant activities.31,32 Previous 
chemical investigation of its leaves reported to isolate polyphenols and tannins, whether from its 
fruits, several rocagloic acid derivatives33  were isolated.   
 
Extraction and Isolation 
The MeOH extract of leaves of A. cucullata (26 
g) was chromatographed over Diaion HP-20 to 
exclude the chlorophyll content. The chlorophyll 
free fraction (19.3 g) was then partitioned 
between hexane, EtOAc, and BuOH to get the 
corresponding extracts.  EtOAc extract (3.3 g) 
was subjected to silica gel PSQ100B Column 
chromatography (CC) to afford fractions 2A-2G.  
Fraction 2B (17 mg) was subjected to preparative 
HPLC to get compounds 19, 20, 22, and 23.  
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Fraction 2D (319 mg) was chromatographed over silica gel 60N to afford fractions 3A-3E. 
Fraction 3B was determined as compound 24 (4.1 mg). Fraction 3D (89.4 mg) was subjected to 
silica gel 60N to afford fractions 3D1- 3D4. From 3D3 (13.6 mg), compound 25 (3.5 mg) was 
obtained after performing Sephadex LH20 CC. Fraction 2F (193 mg) was subjected to Silica gel 
60N CC to afford fractions 4A-4E. From 4B (14 mg), compounds 18 (1.5 mg) and 21 (2.4 mg) 
were obtained after performing ODS flash CC. Fraction 4D (54 mg) was subjected to silica gel 
60N column chromatography to afford fractions 4D1- 4D5. From 4D3 (3.0 mg) and 4D4 (2.2 
mg), compounds 26 (1.0 mg) and 27 (0.8 mg), were obtained, respectively, after Sephadex LH20 
CC. Hexane extract (920 mg) was chromatographed over silica gel PSQ100B to afford fractions 
5A-5E. Compound 28 (8.4 mg) was isolated from fraction 5C (53 mg) after performing ODS 
flash CC (Figure 3-16). 
 
 
 
                       
Fig. 3-15 Effect of hexane (HE), EtOAc (EA), BuOH (BU), and Aqueous (AQ) extracts of  
A. cucullata, and TRAIL, alone or in combination, on the viability of AGS cells.  
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Fig. 3-16 Isolation scheme of A. cucullata. 
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C-2: Structure elucidation of compounds 18-28 
 
Bioassay-guided fractionation of the MeOH extracts of its leaves, led to the isolation of 4 new 
compounds (18-21) along with seven known compounds (22-28) from the hexane and EtOAc 
extracts (Figure 3-17).  
 
 
 
 
 
 
 
 
 
 
 
Fig. 1 Chemical structures of AC18-28.  
 
Fig. 3-17 Structures of compounds 18-28. 
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Compound 18 was isolated as an optically active, colorless solid, and was assigned the molecular 
formula C36H40N2O9 on the basis of HRESIMS m/z 667.2601 [M+Na]+ (Calcd. for 
C36H40N2O9Na, 667.2626, ∆ −2.5 mmu), and 1H and 13C NMR spectroscopic data. Its IR 
spectrum showed hydroxyl (3362 cm−1) and carbonyl (1684 cm−1). The 1H and 13C NMR data 
(Figure 3-18) showed the presence of thirteen quaternary carbons, including two amide carbons 
(δC 169.3 and 174.0), fourteen methines, five methylenes, one methyl, and three methoxy groups. 
In the 1H NMR spectrum, signals for three methoxy groups at δ 3.48, 3.86, and 3.89 were found. 
In addition, signals for three aromatic rings similar to those of compound 25, were observed, that 
is, two meta coupled aromatic protons at δ 5.44 (d, J = 2.4)  and 5.99 (d, J = 2.4) indicated a 1, 2, 
3, 5-tetrasubstituted benzene ring (ring A) fused to ring B,  the characteristic AA’BB’ system of 
a p-disubstituted benzene ring (ring D) at δ 6.99 (d, J = 8.8)  and  δ 7.61 (d, J = 8.8), and the 
signals of a monosubstituted benzene ring (ring C) (δ 6.68, 2H, m; δ 6.92, 3H, m). Furthermore, 
two methines at δH 4.00 (s, H-3) and 3.73 (s, H-4) were assigned to be located at ring B, typical 
of a cyclopenta[b]benzopyran skeleton.34 A close inspection of the 1H and 13C NMR data as well 
as COSY and HMBC correlations (Figure 3-19), and comparison with the spectral data of 
compound 27, also indicated the presence of the hydroxytigloyl-1, 4-butanediamide (HTBD) 
moiety, forming an amide linkage with carbonyl C-11 (δC 174.0), which was supported by the 
HMBC correlation  between H2-13 and C-11. The connectivity of ring C, D, and HTBD moiety 
to ring B was assigned on the basis of HMBC correlations. In the HMBC spectrum, a crosspeak 
was observed from δH 7.61 (2H, d, J = 8.8 Hz, H-2’/6’) to δC 86.3 (C-2) indicated that ring D 
was connected to C-2. HMBC correlation from H-3 (δ 4.00, s) to C-2’’/6’’(δC 127.1) indicated 
that the ring C was connected to C-3. HTBD moiety was connected to C-4 on the basis of 
HMBC correlations from both H-3 and H-4 to C-11 of the HTBD moiety (Figure 3-19).  Further 
HMBC correlations from H-3 to C-2, C-4, and C-10, and from H-4 to C-2, C-5, C-5a, and C-10, 
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supported the structure of tricyclic ring moiety. It was evident from the 1H and 13C NMR spectra, 
that C-10 (δC 90.5) was a quaternary carbon contained a hydroxyl group, and N-12 of the 
putrescine (1,4-butanediamide) moiety formed a bond with C-10 to create a five-membered 
cyclic amide, forming a cyclopenta[b]benzopyran skeleton similar to that of cyclofoveoglin 
isolated from Aglaia foveolata.34 Thus the structure of 18 was similar to that of cyclofoveoglin 
with the difference in the butanediamide side chain. Benzoyl moeity of the benzoyl-1,4-
butanediamide side chain of cyclofoveoglin was replaced with a hydroxytigloyl moiety forming 
a hydroxytigloyl-1,4-butanediamide in 18.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3-18 1H and 13C NMR of 18. 
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Fig. 3-19  Selected HMBC correlations of 18. 
 
 
 
 
66 
 
Relative stereochemistry of 18 was determined on the basis of NMR data and from NOE 
correlations (Figure 3-20).  In the 1H NMR spectrum both H-3 and H-4 appeared as singlets, 
which is possible when the dihedral angle is close to 90 degree. Model showed that the angle was 
about 90 degree. Moreover, NOE correlations between H-3 and H-4, from H-3 to H-2’, and from 
H-4 to H-2” were compatible to the proposed structure.  
 
 
 
 
Fig. 3-20  Selected NOE correlations of 18. 
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Compound 19 was isolated as optically active,  colorless oil,  and was assigned the molecular 
formula C20H32O on the basis of HREIMS m/z 288.2468 [M]+ (Calcd. for C20H32O, 288.2453, ∆ 
+1.5 mmu), and 1H and 13C NMR spectroscopic data (Figure 3-21). The 13C NMR spectrum 
showed 20 carbon signals including the signals for three methyls, nine methylenes, four methines 
and four quaternary carbons. The 13C NMR spectrum  included three double bonds (δC 147.7, 
146.9, 139.0, 115.6, 113.3, and 107.5) and one secondary hydroxyl group at δC 65.7.  Its 1H 
NMR spectrum indicated the existence of three tertiary methyl groups at δH 0.92, 0.82, and 0.70, 
corresponding to Me-18, Me-19, and Me-20, respectively, along with three methylene groups at 
δH 5.20 and 5.02 (H2-15),  4.97 (H2-16), and at  4.87 and 4.56 (H2-17). A triplet- triplet at δH 
3.82 (J=4.1, 11.4 Hz) was also assignable to the hydrogen attached to an hydroxy-bearing carbon 
at δC 65.7, and was unequivocally determined to be located between C-1 and C-3, on the basis of 
COSY correlation (Figure 3-22).  Thus, from the 1H and 13C NMR spectroscopic data along with 
HMBC correlations data, it was evident that 19 was a labdane diterpene containing 2β-hydroxy 
group.35  
68 
 
 
 
 
Fig. 3-21 1H and 13C NMR of 19. 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3-22  COSY and HMBC correlations of 19. 
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The relative stereochemistry of 19 was assigned on the basis of both coupling constant data and 
NOE correlations (Figure 3-23). The coupling constants for H-1β/H-2 and H-3β/H-2 were 11.4 
Hz, while those for H-1α/H-2 and H-3α/H-2 were 4.1 Hz, indicating that H-2 was α-axial. NOE 
correlations from H-2 to Me-19, and Me-20 indicated the alpha orientation for Me-19 and Me-20.  
NOE correlations from Me-20 to H-2, H-6α are also compatible with the proposed configuration. 
Moreover, NOE correlations between H-5 and H-9, indicated that both H-5 and H-9 were β-
oriented. Thus the compound was determined as 2β-hydroxy-labda- 8(17), 13(16), 14-triene. 
 
 
 
 
 
 
                                                   
 
Fig. 3-23   Couplings  NOE correlations of 19. 
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Compound 20 was isolated as optically active,  colorless oil,  and was assigned the same 
molecular formula C20H32O of 19, as indicated by HREIMS m/z 288.2468 [M]+ (Calcd. for 
C20H32O, 288.2445, ∆ −0.8 mmu). The 1H and 13C NMR spectroscopic data (Figure 3-24) of 20 
were also comparable with those of 19, with the exception of the signals for H-2, that appeared 
as a quintuplet at δ 4.14 (J = 5.2 Hz) in 20, whereas the H-2 of 19 appeared as a triple-triplet at δ 
3.82 (J = 11.4 and 4.1 Hz). In 19, H-2 appeared as a quintuplet at δH 4.14 (J = 5.2 Hz), due to its 
equatorial-equatorial or equatorial-axial coupling with H-3 and H-1. This evidence suggested 
that 20 was an isomer of 19 differing in the configuration at C-2. In 20, alpha orientation was 
assigned for its 2-OH group, and H-2 was assigned as β-equatorial based on its multiplicity 
pattern and coupling constant value.  
 
 
 
                                                      Fig. 3-24   1H and 13C NMR of 20. 
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The relative stereochemistry was assigned on the basis of NOE correlations (Figure 3-25).  
NOE correlations from H-2 to H-1β, correlations between H-5 and H-9, and between Me-
19 and Me-20 are compatible with the proposed configuration. Thus the compound was 
determined as 2α-hydroxy-labda- 8(17), 13(16), 14-triene. 
 
 
 
 
 
 
 
Fig. 3-25   Couplings  and NOE correlations of 20. 
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Compound 21 was isolated as optically active, colorless solid,  and was assigned the molecular 
formula C30H50O5 on the basis of HRESIMS m/z 513.3546 [M+Na]+ (Calcd. for C30H50O5Na, 
513.3550, ∆ −0.5 mmu), and 1H and 13C NMR spectroscopic data (Figure 3-26). Its IR spectrum 
showed the presence of hydroxyl (3398 cm−1) and carbonyl group (1698 cm−1). The 13C NMR 
data showed the presence of thirty carbons, including five methyls, thirteen methylenes, five 
aliphatic methines, and seven quaternary carbons, which was confirmed from the DEPT spectra. 
The 1H NMR spectrum displayed signals due to a cyclopropyl methylene (δH 0.59 and 0.80, both 
d, J = 4.2 Hz), five tertiary methyls (δH 0.91, 1.00, 1.06, 1.15, and 1.20, each s), a hydrogen 
attached to hydroxy-bearing methine carbon group (δH 3.35, dd, J=8.4 and 1.6 Hz), and two 
hydroxymethyls (δH 3.44, 3.75, ABq,  J = 11.9 Hz, H2-29; δH 3.77, dd, J = 11.2, 3.3, H-21a, and 
3.60, dd, J= 11.2, 4.9, H-21b;). The 1H and 13C NMR spectra were typical for triterpenes of the 
cycloartane series. The high field pair of doublets at δH 0.80 and 0.59 ppm with a geminal 
coupling constant (J = 4.2 Hz) was characteristic for this class of triterpenes.36 The typical 3-keto 
carbonyl was found in the 13C NMR spectrum at δ 218.6 ppm. Thus, 21 had the same basic 
skeleton as a previously reported cycloartane derivative,37 with C-3 carbonyl and C-28 
hydroxymethyl groups, but with a structurally different side chain at position C-17. The side 
chain moiety consisted of an OH-substituted quaternary carbon at C-25 (δ 73.1) with two 
geminal methyl groups (C-26 and C-27, δH 1.15 and 1.20, δC 23.3 and 26.6), a hydroxymethyl 
(C-21), a substituent instead of a secondary methyl group, along with a hydroxymethine at C-24 
(δH 3.35, dd, J=8.4 and 1.6 Hz; δC 78.8). Therefore, 21 was assigned the structure as 21, 24, 25, 
28-tetrahydroxycycloarten-3-one.  
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Fig. 3-26   1H and 13C NMR of 21. 
 
 
 
Relative configuration of 21 was determined on the basis of NOESY correlations depicted in the 
figure 3-27. NOESY correlations showed that the relative configuration of the basic skeleton of 
21 was similar to that of the aforementioned compound isolated by Li, et al., 2009.37 Recently, 
the differentiation of 24R-and 24S stereomers of cycloartane-type triterpenes using 13C NMR 
techniques have been reported.38 The chemical shift of C-24 of 24R-type compound was at δC 
79.6, and that of S-type compound, it was at 78.8 in CDCl3. Chemical shift of C-24 of 21 was 
resonated at δC 78.8, thus the configuration of 21 was deduced as 24S, and determined as (24S)- 
21, 24, 25, 28-tetrahydroxycycloartane-3-one. 
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Fig. 3-27  NOE correlations of 21. 
 
 
 
 
 
Compounds 22-28 were isolated as known compounds, and their structures were determined by 
comparing the NMR data (Appendix-I) with those of literature. Compounds 22-24 were 
determined as ent-13-epi-mannol39 (22), kaur-15-en-17-ol40 (23), and ent-2β-
hydroxymanool41 (24). Compounds 25-26 were rocagloic acid derivatives and were determined 
as 1-O-formylrocagloic acid (25) and 3’-hydroxyrocagloic acid (26).33 Compounds 27 and 28 
were identified as dasyclamide42 and 2β,15-dihydroxy-ent-labda-8(17),13E-diene,43 respectively. 
Of the isolates, 25 and 26 were previously from this plant, whereas others were first isolated 
from this plant. 
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C-3: Activity of the isolates (18-28) 
 
The isolated compounds (18–28) were evaluated for their activity in overcoming TRAIL-
resistance in AGS cells. As shown in Figure 3-28, treatment with 100 ng/mL TRAIL for 24 
h resulted in only a slight decrease in cell viability (91 ± 4.5%). Luteolin, used as positive 
control, produced about 62% more inhibition along with TRAIL than the agent alone at 17.5 
µM. Treating cells with 1.25 or 2.5 µM of 18 along with TRAIL (100 ng/mL) resulted in 45 
and 57% more inhibition than the agent alone, showing its strong activity in overcoming 
TRAIL-resistance. Treating cells with 100 ng/mL TRAIL and 1 or 2 nM of 25 reduced cell 
viability to 68 ± 5% and 36.5 ± 1.3% of control levels (p < 0.01), respectively, which was 24 
and 38% more than the agent alone, showing its strong activity in overcoming TRAIL-
resistance. Treating cells with 100 ng/mL TRAIL and 10 or 20 nM of 26 resulted in 33 and 
37% more inhibition than the agent alone, indicating its strong activity. Combined treatment 
of TRAIL and 22 (5 or 10 µM) resulted in 23 and 29% more inhibition than the agent alone, 
indicated its moderate activity in overcoming TRAIL-resistance. Compounds 19, 20, 21, 23, 
24, 27, and 28 along with TRAIL did not produce any significant reduction in the cell 
viability suggesting its inactivity in overcoming TRAIL resistance.  
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Fig. 3-28 Effect of compounds 18, 22, 25, 26, and luteolin (positive control: Lut) and TRAIL treatment, 
alone and in combination, on the viability of AGS cells. Cells were seeded in a 96-well culture plate (6 × 
103 cells per well) for 24 h and then treated with indicated concentrations of the compounds and/or 
TRAIL (100 ng/ml) for 24 h. Cell viability was determined by Fluorometric Microculture Cytotoxicity 
Assay (FMCA). The bar represents the means (n = 3 ± SD). Significance was determined by Student’s t-
test p < 0.01 (**) vs. control (Con). 
 
 
 
 
 
77 
 
  References 
 
 
(1) Ahmed, N. The Wild Flower of Bangladesh, 1st edition; The University Press Ltd.: Dhaka, 
1997; p. 43. 
(2) Khosa, R. L.; Wahi, A. K.; Mukherjee, A. K. J. Indian Chem. Soc. 1979, 56, 935. 
(3) Gopinath, K. W.; Mohamed, P. A.; Kidwai, A. R. J. Indian Chem. Soc. 1963, 1, 98.   
(4) Kaufmann, H.; Wehrli, W.; Reichstein, T. Helv. Chim. Acta 1965, 48, 65-82.  
(5) Kaufmann, H.  Helv. Chim. Acta 1965, 48, 83-94.  
(6) Siddiqui, B. S.; Sultana, R.; Begum, S.; Zia, A.; Suria, A. J. Nat. Prod. 1997, 60, 540-544.  
(7) Sanduja, R.; Lo, W. Y. R.; Eular, K. L.; Alam, M. J. Nat. Prod. 1984, 47, 260-265.  
(8) Kasai, R.; Okihara, M.; Asakawa, J.; Mizutani, K.; Tanaka, O. Tetrahedron 1979, 35, 
1427-1432.  
(9) Yamauchi, T.; Abe, F.; Wan, A. S. C. Chem. Pharm. Bull. 1987, 35, 2744-2749.    
(10) Tori, K.; Ishii, H.; Wolkowski, Z. W.; Chachaty, C.; Sangare, M.; Piriou, F.; Lukacs, G. 
Tetrahedron Lett. 1973, 35, 1077-1080. 
(11) Sy, L.-K.; Brown, G. D. J. Nat. Prod. 1998, 61, 987-992. 
(12) D'Abrosca, B.; DellaGreca, M.; Fiorentino, A.; Monaco, P.; Previtera, L.; Simonet, A. 
M.; Zarrelli, A. Phytochemistry 2001, 58, 1073-1081. 
(13) Lei, Y.; Wu, L.-J.; Shi, H.-M.; Tu, P.-F. Helv. Chim. Acta 2008, 91, 495-500. 
(14) Ahmad, B.; Hamburger, M.; Gupta, M. P.; Solis, P. N.; Hostettmann, P. Phytochemistry 
1991, 30, 3781-3784. 
(15) Kanchanapoom, T.; Kasai, R.; Yamasaki, K. Phytochemistry 2002, 59, 557-563. 
 
(16) Li, J.-Z.; Qing, C.; Chen, C.-X.; Hao, X.-J.; Liu, H.-Y. Bioorg. Med. Chem. Lett. 2009, 
78 
 
19, 1956-1959. 
(17) Cheenpracha, S.; Karalai, C.; Rat-a-pa, Y.; Ponglimanont, C.; Chantrapromma, K. Chem. 
Pharm. Bull. 2004, 52, 1023-1025. 
(18) Frese, S.; Frese-Schaper,  M.; Andres, A.-C.; Miescher, D.; Zumkehr, B.; Schmid, R. A. 
Cancer Res. 2006, 66, 5867-5874. 
(19) Kirtikar, K.R.; Basu, B.D. Indian Medicinal Plants; Bishen Singh- Mahendrapal Singh: 
India, 1975. 
(20) Karou, D.; Nadembega, W. M. C.; Ilboudo, D. P.; Ouermi, D.; Gbeassor, M.; Souza, C. 
D.; Simpore, J. Afr. J. Biotechnol. 2007, 6, 2953-2959. 
(21) Yang, S.-W.; Abdel-Kader, M.; Malone, S.; Werkhoven, M. C. M.; Wisse, J. H.; 
Bursuker, I.; Neddermann, K.; Fairchild, C.; Raventos-Suarez, C.; Menendez, A. T.; Lane, 
K.; Kingston, D. G. I. J. Nat. Prod. 1999, 62, 976-983.  
(22)  Yoon, K. D.; Jeong, D. G.; Hwang, Y. H.; Ryu, J. M.; Kim, J. J. Nat. Prod. 2007, 70, 
2029-2032. 
(23) Okuyama, T.; Hosoyama, K.; Kiraga, Y.; Kurono, G.; Takemoto, T. Chem. Pharm. Bull. 
1978, 26, 3071-3074.  
(24) Laryea, D.; Isaksson, A.; Wright, C. W.; Larsson, R.; Nygren P. Invest. New Drugs 2009, 
27, 402-411. 
(25) Ansah, C.; Gooderham, N. J. Am. J. Pharmacol. Toxicol. 2009, 4, 177-185. 
(26) Dassonneville, L.; Lansiaux, A.; Wattelet, A.; Wattez, N.; Mahieu, C.; Van Miert, S.; 
Pieters, L.; Bailly,  C. Eur. J. Pharmacol. 2000, 409, 9-18. 
(27) Ishibashi, M.; Ohtsuki, T. Med. Res. Rev. 2008, 28, 688-714. 
(28) Kikuchi, H.; Ohtsuki, T.; Koyano, T.; Kowithayakorn, T.; Sakai, T.; Ishibashi, M.  J. Nat. 
Prod. 2007, 70, 1910-1914. 
79 
 
(29) Das, A. K.; Shahid, I. Z.; Choudhuri, M. S.K.; Shilpi, J. A.; Ahmed, F. Orient. Pharm. 
Exp. Med. 2005, 5, 37-42. 
(30) Kirtikar, K. R.; Basu, B. D. Indian Medicinal Plants;  International Book Distributors: 
India, 1999; pp 553-554. 
(31) Das, A. K.; Shahid, I. Z.; Ahmed, F.; Moniruzzaman, M.; Masud, M. M. Dhaka Univ. J. 
Pharm. Sci. 2005, 4, 83-85. 
(32) Basak, U. C.; Das, A. B.; Das, P. Bull. Mar. Sci. 1996, 58, 654-659. 
(33) Chumkaew, P.; Kato, S.; Chantrapromma K. Chem. Pharm. Bull. 2006, 54, 1344-1346. 
(34) Salim, A. A.; Chai, H. B.; Rachman, I.; Riswan, S.; Kardono, L. B.; Farnsworth, N. R.; 
Carcache-Blanco, E. J.; Kinghorn, A. D. Tetrahedron 2007, 63, 7926-7934. 
(35) Garbarino, J. A.; Chamy, M. C.; Piovano, M.; Espinoza, L.; Belmonte, E. Phytochemistry 
2004, 65, 903-908. 
(36) Weber, S.; Puripattanavong, J.; Brecht, V.; Frahm, A. W. J. Nat. Prod. 2000, 63, 636-642.  
(37) Li, F.; Awale, S.; Zhang, H.; Tezuka, Y.; Esumi, H.; Kdota, S.  J. Nat. Prod. 2009, 72, 
1283-1287. 
(38) Greca, M. D.; Florentino, A.; Monaco, P.; Previtera, L. Phytochemistry 1994, 35, 1017-
1022. 
(39) Nagashima, F.; Tanaka, H.; Asakawa, Y. Phytochemistry 1996, 42, 93-96. 
 
 
 
 
(40) Zhang, G.; Shimokawa, S.; Mochizuki, M.; Kumamoto, T.; Nakanishi, W.; Watanabe, T.; 
Ishikawa, T.; Matsumoto, K.; Tashima, K.; Horie, S.; Higuchi, Y.; Dominguez, O. P. J. 
80 
 
Nat. Prod. 2008, 71, 1167-1172. 
(41) Bohlmann, F.; Kramp, W.; Grenz, M.; Robinson, H.; King, R. M. Phytochemistry 1981, 
20, 1907-1913. 
(42) Chaidir; Lin, W. H.; Ebel, R.; Edrada, R.; Wray, V.; Nimtz, M.; Sumaryono, W.; Proksch, 
P. J. Nat. Prod. 2001, 64, 1216-1220. 
(43) Zdero, C.; Bohlmann, F.; Niemeyer, H. M. Phytochemistry 1990, 29, 3247-3253.  
 
 
 
 
 
 
 
81 
 
 
Chapter 4:  
Study of Mechanism of TRAIL-resistance overcoming activity  
of compound 25 
 
I. Introduction 
In the present screening program for TRAIL-resistance overcoming activity, compound 25 was 
isolated from A. cucullata.  This compound was previously isolated from this plant and reported 
to exert profound cytotoxic activity against a number of cancer cell lines.1  In this study we 
found that it sensitized human gastric adenocarcinoma (AGS) cells to TRAIL at lower 
concentrations (1 and 2 nM). As it showed most potent activity in overcoming TRAIL-resistance, 
we investigated the molecular mechanisms behind its activity.    
 
 
 
 
Fig. 4-1 TRAIL-mediated apoptosis 
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II. Compound 25 sensitizes AGS cells to TRAIL-mediated cell growth inhibition and 
induction of apoptosis 
Treatment of AGS cells with TRAIL (100 ng/ml) along with 25 (1 and 2 nM) for 24 h resulted in 
22 and 38% more inhibition compared to 25 alone suggesting a possible synergism between the 
two agents (Figure 4-2). To ascertain whether the decrease in cell viability produced by the 
combined treatment of TRAIL and 25 was caused by apoptotic cell death, we checked the treated 
cells displaying apoptotic morphology by Hoechst staining. After 24 h treatment with 25 and/or 
TRAIL, AGS cells were observed under fluorescence microscope. We observed increased 
number of cells with apoptotic nuclei in the cells treated with 25 (1 and 2 nM) and TRAIL (100 
ng/ml). The apoptotic nuclei containing fragmented chromatins stained more brightly in these 
cells than the normal cells.2 As shown in figure 4-2, no cells with apoptotic nuclei were found in 
the control cells. And a very few number of cells with apoptotic nuclei was found in the cells 
treated with 25 or TRAIL alone. These results indicated that the cell growth inhibition produced 
by the combined treatment of 25 and TRAIL was due to apoptosis.  
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Fig. 4-2 Effect of 25 and TRAIL treatment, alone and in combination, on cell growth and 
apoptosis of AGS cells. Cell growth analysis: (a) AGS cells were treated as given under 
'Experimental', and cell growth was determined by FMCA. (b) Apoptosis detection: AGS cells 
were grown on cell culture glass-bottom dishes and treated as described in 'Experimental' and 
apoptosis was determined by Hoechst 33342 stain. Representative photomicrographs from each 
treatment group showing induction of apoptosis (bright fluorescence).  
 
** 
** 
(a) 
(b) 
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III. Effect of combined treatment of 25 and TRAIL on caspase-3/7 activity 
 
Caspase-3/7 are known as effector caspases, and after activated by the initiator caspases 
(Caspase-8/9), it induce apoptosis. During investigating the molecular mechanisms underlying 
the apoptosis produced by compound 25, we checked the caspase-3/7 activity using caspase-3/7 
assay kit (Promega) after 12 h of treatment. The results showed that the combined treatment of 
25 at 1 and 2 nM along with TRAIL (100 ng/ml) increased caspase-3/7 activity by 2.2 and 2.4-
fold, respectively, to that of control (Figure 4-3). 
 
 
 
Fig. 4-3 Effect of 25 and TRAIL treatment, alone and in combination, on caspase 3/7 activity.  
AGS cells were treated with the indicated concentrations of 25 and TRAIL for 12 h.  Activity was 
measured using the Caspase-Glo 3/7 assay kit.  Values on top of the columns represent relative 
fold-induction compared to control (n = 3).  The significance was determined with Student’s t-test 
(**, p< 0.01; *, p< 0.05 vs. control).   
 
85 
 
IV. Effect of 25 on DR4 and DR5 mRNA expression 
 
To understand the molecular mechanism underlying the apoptosis produced by combined 
treatment of TRAIL and 25 in AGS cells, we next investigated the changes in the expression of 
death receptor pathway related gene using the real time quantitative RTPCR analysis. TRAIL-
mediated apoptotic pathway begins with the binding of TRAIL to the death receptors DR4/DR5,4 
we checked both DR4 and DR5 gene expression in AGS cells after 3, and 6 h of treatment with 
compound 25. As shown in Figure 4-4, treatment of AGS cells to 25, upregulated the mRNA 
expression of both DR4 and DR5 after 3 and 6 h of treatment. 25 enhanced DR4 mRNA 
expression 1.68 and 1.64-fold, compared to control, after 3 h, at 1 and 2 nM, respectively. After 
6 h, it caused 1.31- fold induction of DR4 mRNA expression at 2 nM (Figure 4-4a). It also 
significantly enhanced gene expressions of DR5 by 1.42 and 1.32-fold, after 3 and 6 h, 
respectively, at 2 nM (Figure 4-4b). The enhancement effect of 25 on DR4 and DR5 mRNA 
expression after 3 and 6 h of treatment, correlated well with the caspase-3/7 activity after 12 h 
and sensitization of cells to TRAIL-induced apoptosis TRAIL after 24 h treatment.3 
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Fig. 4-4 Effect of 25 on DR4 (a) and DR5 (b) mRNA expression in AGS cells. AGS cells were 
treated with the indicated concentrations of 25, and the expression was determined by real-time 
RT-PCR.  The relative quantification of the target gene expression was normalized to the mRNA 
expression of an endogenous reference gene, GAPDH.  Values on top of the columns represent 
the relative fold-induction compared to control (n = 9).  The significance of differences was 
determined with Student’s t-test ((**, p< 0.01; *, p< 0.05 vs. control).     
 
(a) 
(a) 
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V. Effect of Compound 25 on normal (293T) cells 
 
To find out whether it exerts any cytotoxicity towards normal cells, we then examined the effect 
of combined treatment of TRAIL (100 ng/ml) and 25 (1 or 2 nM), on human renal epithelial cell 
lines (293T). Results showed that it did not cause any cytotoxicity towards this cells (Figure 4-5). 
Thus, it can be concluded that 25 decreased cell viability selectively in AGS cancer cells without 
affecting the normal 293T cells.  
 
 
 
 
Fig. 4-5 Effect of 25 and TRAIL treatment, alone and in combination, on cell growth of human 
renal epithelial (293T) cells.  
 
 
 
 
88 
 
VI. Conclusion 
Compound 25, a rocagloic acid derivative containing a cyclopenta [b] benzofuran ring skeleton, 
was previously reported for its potent cytotoxic activity against a variety of tumor cells.1 In 
addition, some other rocagloic acid derivatives, as rocaglamide, silvestrol, etc., were reported for 
cytotoxic activity against several cancer cells.5-8 Silvestrol, a potential anticancer rocaglate 
derivative from Aglaia foveolata, was reported to induce apoptosis in LNCaP cells through the 
mitochondrial/apoptosome pathway.9 Here, we found for the first time, its TRAIL-resistance 
overcoming activity in AGS cell lines with no effect on normal human (293T) cells. It sensitizes 
AGS cells to TRAIL by upregulating both DR4 and DR5 mRNA expression. 
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Chapter 5 
 
A. General Experimental Procedure 
Optical rotations: JASCO P-1020 polarimeter.   
UV spectra: Shimadzu UV mini-1240 spectrometer.  
CD spectra: JASCO J-720WI spectropolarimeter.   
IR spectra (ATR): JASCO FT-IR 230 spectrophotometer.  
NMR spectra: JEOL A 400, JEOL A 500, ECP 600, and ECA 800 spectrometers (deuterated 
solvents, the chemical shift of which was used as an internal standard).  
FABMS: JEOL JMS-AX500 spectrometer  
HRFABMS: JEOL HX-110A spectrometer,  
HREIMS: JEOL JMS-AX500 spectrometer  
HRESIMS: Thermo scientific Exactive 
 
Cell cultures: AGS cells were derived from Institute of Development, Aging and Cancer, 
Tohoku University; Cells were cultured in RPMI-1640 medium (Wako) with 10% FBS. Cultures 
were maintained in a humidified incubator at 37 °C in 5% CO2/95% air. 
 
TRAIL-resistance-overcoming activity: TRAIL-resistance-overcoming activity of the isolated 
compounds was assessed by comparison of cell growth inhibitory activity in the presence and 
absence of TRAIL against TRAIL-resistant human gastric adenocarcinoma (AGS) cell lines.1  
AGS cells were seeded in a 96-well culture plate (6 × 103 cells per well) in 200 µL of RPMI 
medium containing 10% FBS. Cells were incubated at 37 °C in a 5% CO2 incubator for 24 h. 
Then the test samples with or without TRAIL (100 ng/mL) at different doses were added to each 
well. After 24 h incubation, the cells were washed with PBS, and 200 µL of PBS containing 
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fluorescein diacetate (10 µg/mL) was added to each well. The plates were then incubated at 
37 °C for 1 h, and fluorescence was measured in a 96-well scanning spectrofluorometer at 538 
nm, following excitation at 485 nm.  
 
Fluorometric Microculture Cytotoxicity Assay (FMCA): AGS cells were seeded in a 96-well 
culture plate (6 × 103 cells per well) in 200 µL of RPMI medium containing 10% FBS. Cells 
were incubated at 37 °C in a 5% CO2 incubator for 24 h. Then the test samples with or without 
TRAIL (100 ng/mL) at different doses were added to each well. After 24 h incubation, the cells 
were washed with PBS, and 200 µL of PBS containing fluorescein diacetate (10 µg/mL) was 
added to each well. The plates were then incubated at 37 °C for 1 h, and fluorescence was 
measured in a 96-well scanning spectrofluorometer at 538 nm, following excitation at 485 nm.2,3  
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Methodology for Chapter 2: Exploration of Actinomycetes 
 
Collection and Isolation: CKK105 and CKK190 were isolated from a soil sample collected 
from Sakazuki Forest, Wakaba Ward, Chiba City, whereas, CKK237 was isolated from a soil 
sample collected from Chikou Mountain Park, Sayama city, Saitama Prefecture, Japan in 2007. 
From the collected soil samples, actinomycetes strains (CKK105, CKK237, and CKK190) were 
separated on humic acid-vitamin (HV) agar,4 a medium for the selective isolation of soil 
actinomycetes.  
 
Identification: CKK105 was identified as Streptomyces sp. IFM 10937 by Professor Yuzuru Mikami, 
Medical Mycology Research Center, Chiba University, Japan, where a voucher specimen was deposited with the 
code IFM 10937.  
 
Fermentation: Spores of the strain growing on solid Waksman medium were inoculated into a 
1L round bottom flask containing 100 mL liquid medium,5  and then incubated at 28 °C for 5 
days with reciprocal shaking at 200 rpm to produce seed culture.  The seed culture (10 mL) was 
then inoculated into each of 10 3 L flasks, each containing 500 mL of liquid Waksman medium, 
and incubated at 28 °C for 7 days with reciprocal shaking at 200 rpm to get 5 L fermentation 
broths.  
 
Marfey Analysis: To 50 µL of aqueous solution (2 mg/mL) of 2 were added 20 µL of 1 M 
NaHCO3 and then 100 µL 1% (w/v) FDLA (Tokyo Chemical Industry Co. Ltd., Japan) in 
acetone. The solution was vortexed and incubated at 37 °C for 1 h, after which the reaction was 
quenched with 20 µL of 1 M HCl. Samples were diluted with 810 µL of acetonitrile and 10 µL 
of this solution was analyzed by reversed-phase HPLC systems (Shimadzu, Japan).  Separations 
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were carried out on a Capcell Pak C18-ACR (250 mm × 4.6 mm) column, heated at 40 °C. For 
gradient elution in HPLC, mobile phase A was prepared from 0.1 M NH4OAc in aqueous 
solution, adjusted to pH 3-4 by addition of TFA, and the mobile phase B was acetonitrile.  In all 
cases, linear gradients started with 15% B and finished with 100% B in 85 min. The system was 
allowed to equilibrate for 10 min at 15% B prior to the next analysis. The flow rate was 0.75 
mL/min, with UV detection at an absorbance of 340 nm by photodiode array detection. 
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Compound 1: colorless solid; [α]17 D −8.7 (c 0.28, MeOH); UV (MeOH) λmax (log ε) 211 (3.9), 
263 (3.2) nm; CD (MeOH) λext nm (∆ε) 210 (+9.8), 235 (+3.3); IR (ATR) vmax 3281 (br), 2929, 
1651, 1437, 1266 cm−1; For 1H and 13C NMR data, see Appendix-I;  (−)-HRFABMS m/z 
290.1388 [M−H]− (calcd for C16H20NO4, 290.1392)  
 
Compound 2: Colorless solid; [α] 17 D −43.8 (c 0.12, MeOH); UV(MeOH) λmax (log ε) 205 (3.7), 
279 (2.8) nm;  CD (MeOH) λext nm (∆ε) 208 (+6.7), 234 (+1.4); IR (ATR) vmax 3252 (br), 2928, 
1606, 1508, 1399, 1267 cm−1; For 1H and 13C NMR data, see Appendix-I; (−)-HRFABMS m/z 
248.1290 [M−H]− (calcd for C14H18NO3, 248.1287) 
 
 
Compound 3: Yellowish solid; For 1H and 13C NMR data, see Appendix-I;  
 
 
Compounds 4-11: For 1H and 13C NMR data, see Appendix-I; 
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C. Methodology for Chapter 3: Exploration of Medicinal Plants of 
Bangladesh 
 
C-I.  Vallaris solanaceae 
Plant Material: Aerial parts of V. solanaceae without flower was collected from Satkhira, 
Bangladesh in June, 2005 after flowering and taxonomically validated by the experts at 
Bangladesh National Herbarium (accession number: 31287), where a voucher specimen was also 
deposited for future reference.  The air-dried plants were subjected to grinding before extraction.  
 
Extraction and Isolation: The dried and ground plant parts of V. solanaceae (1.1 kg) was 
extracted with MeOH (20 L) for 7 days at room temperature followed by evaporation and 
vacuum desiccation to get the crude extract (70 g).  The extract was then chromatographed over 
Diaion HP-20 (4.5 × 35 cm; particle size 250-850 µm) to exclude the chlorophyll content. The 
Chlorophyll free fraction (35 g) was then suspended in 10% aq. MeOH (400 mL) and partitioned 
between hexane, EtOAc, and BuOH (200 mL × 4).  EtOAc extract (2.64 g) was subjected to 
Silica gel PSQ100B Column chromatography (4.2 × 30 cm, 300 g) using CHCl3-MeOH as 
solvent system with increasing polarity to afford seven fractions, A-G.  Fraction B (450 mg) was 
chromatographed over silica gel PSQ-100B (4.2 × 30 cm, 80 g) using hexane-acetone (9:1 - 0:1) 
to afford five fractions, B1- B5. Fraction B2 was determined as β-sitosterol (15 mg). Compound 
12 (4.5 mg) was isolated from fraction B4 (150 mg) after performing ODS HPLC [Senshu Pak 
ODS-5251-S, 2.0 × 25 cm; MeCN:H2O (2:1); flow rate: 5 mL/min; UV254 detection; tR 20 min). 
Fraction C (800 mg) was subjected to ODS flash column chromatography (1.0 × 40 cm, particle 
size: 100-200 mesh; 12 g) using MeOH:H2O (2:1) as eluent to get four fractions, C1-C4. 
Compound 13 (2.8 mg) was isolated from fraction C2 (300 mg) after chromatographed over 
LH20 (1.0 × 40 cm) with MeOH followed by Silica gel PSQ-100B column chromatography (1.0 
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× 40 cm; 5 g) using hexane-acetone (1:1 - 2:3) as eluent. Fraction E (400 mg) was subjected to 
Silica gel PSQ-100B column chromatography (3.0 × 50 cm; 20 g) using CHCl3:MeOH (13:1 - 
0:1) to afford fractions E1-E3.  Fraction E2 (40 mg) underwent ODS flash column 
chromatography (2.5 × 40 cm; particle size: 100-200 mesh) with MeOH: H2O (1:2) to yield 
compound 14 (2.6 mg).  
 
Hydrolysis of 14: Compound 14 (1.5 mg), was treated with β-glucosidase (7.0 units/mg, Sigma 
Chemical Co., USA, 2.0 mg), capable to catalyze the hydrolysis of β-D-glucosides, in an AcOH–
AcONa buffer solution (0.1 M, pH 5.0, 2.5 mL).6,7 The mixture was stirred at 37 °C for 23 h, 
extracted with an equal amount of EtOAc (×3), then the EtOAc layer was evaporated under 
reduced pressure. The residue was dried to give the aglycone, verimol K (14a, 0.6 mg).  Aqueous 
layer (0.9 mg) containing sugar mixture (14b) was subjected to hydrolysis using 5% aqueous 
H2SO4 at 95 °C for 90 min.  The mixture was then neutralized by Amberlite IRA96SB AG, and 
was dried by rotary evaporator at reduced pressure. Then the residue was examined by Silica gel 
TLC (Silica gel 60 F254, MERCK) using the eluent EtOAc: MeOH (7:1) to identify glucose and 
apiose by comparing with authentic specimens (Rf values: 0.05, and 0.56 for glucose and apiose, 
respectively). D-Apiose was obtained from its 1,2; 2,3-di-O-isopropylidene derivative 
(Funakoshi Co. Ltd., Japan) after acid hydrolysis8 whereas D-glucose was purchased from Wako 
Pure Chemical Industries Ltd., Japan.  
 
Compound 12 (Vallarisoside): Colorless solid; [α] 24D +24 (c 0.43, MeOH); UV (MeOH) λmax 
270 nm (log ε 5.0); IR (ATR) vmax 3420 (br), 2930, 1740, 1375, 1238, 1050 cm-1; For 1H and 13C 
NMR data, see Appendix-I; HRFABMS m/z 597.3008 [M+Na]+ (calcd for C32H46O9Na, 
597.3040)  
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Compound 13 (3β-O-(α-acofriosyl)-16-anhydrogitoxigenin): Colorless solid; [α]
24
D +6.7 (c 0.03, 
CHCl3); FABMS (NBA) m/z 571 [M+K]+; UV (MeOH) λmax 269 nm (log ε 5). For 1H and 13C 
NMR data, see Appendix-I; 
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Compound 14 (Benzyl 2-O-β-apiofuranosyl-(1   2)-β-D-glucopyranosyl-2, 6-dihydroxy -
benzoate): Colorless amorphous solid; [α] 27D −106 (c 0.13, MeOH); UV (MeOH) λmax 280 nm 
(log ε 4.0); IR (ATR) vmax 3370 (br), 2930, 1715, 1610, 1460, 1070 cm-1; For 1H and 13C NMR 
data, see Appendix-I; HRFABMS m/z 561.1593 [M+Na]+ (calcd for C25H30O13Na, 561.1584)  
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C-II.  Sida acuta 
 
Plant Material: Whole plants of S. acuta was collected from Dhaka, Bangladesh in 2006 and 
taxonomically validated by the experts at Bangladesh National Herbarium (accession number: ), 
where a voucher specimen was also deposited for future reference.  The air-dried plants were 
subjected to grinding before extraction.  
 
Extraction and Isolation: MeOH extract of S. acuta whole plants (9.7 g) was chromatographed 
over Diaion HP-20 (4.5 × 35 cm; particle size 250-850 µm) to exclude the chlorophyll content. 
The Chlorophyll free fraction (8.1 g) was then suspended in 10% aq. MeOH (400 mL) and 
partitioned between hexane, EtOAc, and BuOH. BuOH extract (2.7 g) was subjected to Silica gel 
PSQ100B Column chromatography (2.7 × 55 cm) using EtOAc-MeOH as solvent system with 
increasing polarity to afford four fractions, 2A-2D. Fraction 2B (420 mg) was chromatographed 
over silica gel PSQ-100B (3.5 × 27 cm) using CHCl3-MeOH as solvent system followed by ODS 
flash column chromatography and Sephadex LH20 column chromatography to get compound 15 
(36 mg).  EtOAc extract (1.9 g) was subjected to Silica gel PSQ100B Column chromatography 
(2.5 × 45 cm) using CHCl3-MeOH solvent system with increasing polarity to afford four 
fractions, 3A-3D. Fraction 3B (242 mg) was recrystallized to get compound 17 (40 mg).  
Fraction 3C (831 mg) was chromatographed over silica gel PSQ100B (2.5 × 45 cm) using 
EtOAc-MeOH solvent system to get compound 15 (85 mg) and 16 (332 mg).  
 
Luciferase Assay to Assess the Enhancement of DR5 Promoter Activation:  The procedure 
of assay was the same as previously described.9 Briefly, DLD-1/SacI cells (2 x 105 cells per well), 
a human colon cancer cell line stably transfected with the DR5 promoter-luciferase reporter 
plasmids, pDR5/SacI10 were treated with different concentrations of each isolated compound for 
24 h at 37 °C.  After the medium containing the isolated compounds was removed, cells were 
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lysed in a Cell Culture Lysis Reagent (Promega).  The lysate was measured for 10 sec as relative 
light units by a luminometer and the DR5 promoter activity was evaluated by relative light unit 
of sample compared with that of the control (cells treated with EtOH).   
 
 
Compounds 15-17: For 1H and 13C NMR data, see Appendix-I; 
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C-III.  Amoora cucullata 
 
Plant Material: The leaves of A. cucullata were collected from the Sundarbans’ Mangrove 
Forests, Bangladesh, Bangladesh in November, 2008 and were taxonomically identified by Prof. 
A.K. Fazlul Huq, Forestry and Wood Technology Discipline, Khulna University, Bangladesh. A 
voucher specimen was also deposited there for future reference (F018).  The air-dried plants 
were subjected to grinding before extraction. 
 
Extraction and Isolation 
The dried, ground leaves of A. cucullata (280 g) was extracted with MeOH for 2 days at room 
temperature followed by homogenization and filtration, which then underwent evaporation and 
vacuum desiccation to get the crude extract (26 g).  The extract was then chromatographed over 
Diaion HP-20 (4.5 × 35 cm; particle size 250-850 µm) to exclude the chlorophyll content. The 
chlorophyll free fraction (19.3 g) was then suspended in 10% aq. MeOH (400 mL) and 
partitioned between hexane, EtOAc, and BuOH (350 mL × 4) to get the corresponding extracts.  
EtOAc extract (3.3 g) was subjected to silica gel PSQ100B Column chromatography (2.5 × 54 
cm) using CHCl3-MeOH solvent system with increasing polarity to afford fractions 2A-2G.  
Fraction 2B (17 mg) was subjected to preparative HPLC [Inertsil ODS-3, 1.0 × 25 cm; 
MeOH:H2O (9:1); flow rate: 1.5 mL/min; RI and UV detection at 254 nm] to get compounds 19, 
20, 22, and 23 (tR 30, 32, 40, and 45 min for compounds 19, 20, 22, and 23,  respectively). 
Fraction 2D (319 mg) was chromatographed over silica gel 60N (2.5 × 40 cm) using hexane-
acetone solvent system (13:1 - 0:1) to afford fractions 3A-3E. Fraction 3B was determined as 
compound 24 (4.1 mg). Fraction 3D (89.4 mg) was subjected to silica gel 60N column 
chromatography (2.5 × 40 cm) using hexane-acetone solvent system (7:1 - 0:1) to afford 
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fractions 3D1- 3D4. From 3D3 (13.6 mg), compound 25 (3.5 mg) was obtained after performing 
Sephadex LH20 column chromatography using MeOH as eluent. Fraction 2F (193 mg) was 
subjected to Silica gel 60N column chromatography (2.5 × 40 cm) using CHCl3-MeOH solvent 
system with increasing polarity to afford fractions 4A-4E. From 4B (14 mg), compounds 18 (1.5 
mg) and 21 (2.4 mg) were obtained after performing ODS flash column chromatography using 
75% MeOH. Fraction 4D (54 mg) was subjected to silica gel 60N column chromatography (1.5 × 
40 cm) using hexane-acetone-MeOH solvent system with increasing polarity (5:1:0 --- 0:1:1) to 
afford fractions 4D1- 4D5. From 4D3 (3.0 mg) and 4D4 (2.2 mg), compounds 26 (1.0 mg) and 
27 (0.8 mg) were obtained after performing Sephadex LH20 column chromatography using 
MeOH as eluent. Hexane extract (920 mg) was chromatographed over silica gel PSQ100B (2.0 × 
60 cm) using hexane-acetone-MeOH solvent system with increasing polarity to afford fractions 
5A-5E. Compound 28 (8.4 mg) was isolated from fraction 5C (53 mg) after performing ODS 
flash column chromatography using 75% MeOH as eluent. 
 
Compound 18: colorless solid; [α]17D –63.1 (c 0.1, CHCl3); UV (MeOH) λmax 253 nm (log ε 3.6); 
CD (MeOH) λext nm (∆ε) 253 (−9.1), 280 (+3.8); IR (ATR) vmax 3362 (br), 2931, 1684, 1618, 
1515, 1101, 753 cm-1; For 1H and 13C NMR data, see Appendix-I; HRESIMS m/z 667.2601 
[M+Na]+ (calcd for C36H40N2O9Na, 667.2626).  
 
Compound 19: colorless solid; [α]24D −58.1 (c 0.27, CHCl3); UV (EtOH) λmax 208 nm (log ε 3.7); 
IR (ATR) vmax 3363 (br), 2937, 1715, 1643, 1458, 1031 cm-1; For 1H and 13C NMR data, see 
Appendix-I; HREIMS m/z 288.2468 M+ (calcd for C20H32O, 288.2453). 
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Compound 20: colorless solid; [α]24D –70.5 (c 0.13, CHCl3); UV (EtOH) λmax 208 nm (log ε 4.0); 
IR (ATR) vmax 3411 (br), 2935, 1709, 1641, 1032, 889, 754 cm-1; For 1H and 13C NMR data, see 
Appendix-I; HREIMS m/z 288.2468 M+ (calcd for C20H32O, 288.2445) 
 
Compound 21: Colorless solid; [α]21D  +25.8 (c 0.2, CHCl3); UV (EtOH) λmax 204 nm (log ε 3.8); 
CD(MeOH) λext nm (∆ε) 204 (−0.3), 207 (−0.6); IR (ATR) vmax 3411 (br), 2935, 1709, 1641, 
1032, 754 cm-1; For 1H and 13C NMR data, see Appendix-I; HRESIMS m/z  513.3546 [M+Na]+ 
(calcd for C30H50O5Na, 513.3550). 
 
Compounds 22-28: For 1H and 13C NMR data, see Appendix-I. 
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D.  Methodology for the mechanism study 
 
Hoechst staining:  Apoptosis was detected by staining the treated cells with Hoechst 33342 
reagent (Wako Pure Chemical Industries Ltd., Japan ) as described previously.11,12  Briefly, AGS 
cells (2.5 x 105 cells), suspended in 2 ml of RPMI 1640 medium, were seeded on a 3.5 cm glass-
bottom cell culture dish. After 24 h incubation, the cells were treated with 1 and 2 nM of 
compound 25 and/or 100 ng/mL of TRAIL for 24 h.  Then Hoechst33342 reagent was added to 
each dish (20 μL), incubated at 37oC, and observed under fluorescence microscope (OLYMPUS 
DP72, Japan). Photographs of the stained cells were scanned by Flex Scan S1721.   
 
Caspase-3/7 activity:  Caspase-3/7 activity was measured using Caspase-Glo 3/7 Assay kit 
(Promega) according to the manufacturer’s instructions as described previously.13  Briefly, the 
cells were treated with 0.5, 1.0, and 2.0 nM of compound 25 and/or 100 ng/mL of TRAIL for 12 
h, collected, and lysed.  The cell lysates were incubated with a luminogenic substrate, z-DEVD-
amino-luciferin at room temperature for 1 h and the luminescence was monitored using a 
luminometer (Luminoskan Ascent, Thermo Electron Corporation, Japan). 
 
Real Time RT-PCR Analysis:  Total RNA was extracted from AGS cells (2.5×105 cells) using 
TRIZOL reagent (Invitrogen), according to the manufacturer’s instruction.14,15  cDNAs were 
synthesized from 1µg of total RNA by using SuperScript III Platinum SYBR Green Two-Step 
qRT-PCR Kit  (Invitrogen) as recommended by supplier.  Template cDNA thus obtained was 
incubated with 200 nM of gene-specific primers (Fasmac) and  with a SuperScript III Platinum 
Two-Step qRT-PCR kit with SYBR Green (Invitrogen) in a Mx3000 QPCR System (stratagene).  
The thermal cycling program had an initial incubation (50 °C for 2 min) and an initial 
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denaturation (95 °C for 2 min) and then 40 cycles of denaturation (95 °C for 15 sec), annealing 
and extension (60 °C for 30 sec). The primer sets used were as follows: glyceraldehydes-3-
phosphate dehydrogenase (GAPDH), 5’-ATGGGGAAGGTGAAGGTCG-3’ and 5’-
TAAAAGCAGCCCTGGTGACC-3’; DR5, 5’-GAGCTAAGTCCCTGCACCAC-3’ and 5’-
AATCACCGACCTTGACCATC-3’; DR4, 5’-GGAACTTTCCGGAATGACAA-3’ and 5’-
GTCACTCCAGGGCGTACAAT-3’; A fluorescence signal was collected at the end of each 
cycle. After the reactions were terminated, the signal at each temperature from 60 to 95 °C was 
also collected for the dissociation curve analysis.  All reactions were performed in triplicate to 
confirm reproducibility, and the amount of target mRNA in each sample was normalized with 
that of mean GAPDH, an endogenous control.13 
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SUMMARY 
In search for bioactive natural products with TRAIL-resistance overcoming activity, we 
explored natural resources as actinomycetes, collected in Japan, and medicinal plants of 
Bangladesh. From three soil actinomycetes (CKK105, CKK237, and CKK190) 11 compounds 
(1-11) were isolated along with 2 new compounds (1-2). Among the isolates, compounds 3 and 
10 showed moderate activity whereas 8 and 11 showed strong activity in sensitizing AGS cells 
to TRAIL.  
From three medicinal plants (Vallaris solanaceae, Sida acuta, and Amoora cucullata) of 
Bangladesh, compounds 12-28 were isolated including 6 new ones (12, 14, 18, 19, 20, and 21). 
Compound 22 showed moderate activity, whereas compounds 12, 15, 18, 25, and 26 showed 
strong activity in overcoming TRAIL-resistance in AGS cells. 
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Among the isolated compounds (1-28), 25 showed most potent activity in sensitizing AGS cells 
to TRAIL-induced apoptosis, with no effect in normal cells (293T). It sensitized AGS cells to 
TRAIL by upregulating both DR4 and DR5. 
 
 
 
 
Thus, it is concluded that 25 can be expected to contribute as a lead compound in 
anticancer drug development.  
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Appendix-I 
 
 
Table 1  NMR Spectroscopic Data (CD3OD) for 1 and 2 
 
 1a 2b 
position δC, mult. δH (J in Hz) δC, mult. δH (J in Hz) 
1 130.2, qC  129.8, qC  
2 131.5, CH 6.88, d (2.0) 131.5, CH 6.99, d (2.0) 
3 128.9, qC  128.6, qC  
4 154.6, qC  155.6, qC  
5 115.7, CH 6.62, d (8.3) 116.2, CH 6.71, d (8.3) 
6 128.4, CH 6.86, dd (8.3, 2.0) 127.6, CH 6.93, dd (8.3, 2.0) 
7   38.2, CH2 3.09, dd (13.7, 4.4) 
2.79, dd (13.7, 8.5) 
 
  37.6, CH2 3.20, dd (14.4, 4.1) 
2.83, dd (14.4, 9.0) 
 8 57.8, CH 4.39, dd (8.5, 4.4)   57.9, CH 3.67, dd (9.0, 4.1) 
9 172.7, qC  174.0, qC  
10   29.3, CH2 3.23, d (7.1)   29.4, CH2 3.27, d (7.1) 
11 124.3, CH 5.19, t (7.4) 123.9, CH 5.32, t-like (7.4) 
12 132.6, qC  132.9, qC  
 13   25.9, CH3 1.71, s   26.0, CH3 1.71, br s 
14   17.9, CH3 1.69, s   17.8, CH3 1.71, br s 
-CO 179.8, qC    
-COCH3   22.7, CH3 1.88, s   
 
a Recorded at 600 MHz. b Recorded at 400 MHz. 
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1H NMR (600 MHz) and 13C NMR (150 MHz) Spectra (CD3OD) for 1  
 
 
 
 
  
 
 
1H NMR (400 MHz) and 13C NMR (100 MHz) Spectra (CD3OD) for 2 
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                 HMQC spectra (CD3OD) for 1 
 
 
              HMBC spectra (CD3OD) for 1 
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Table 2  NMR Spectroscopic Data (CD3OD) for 3 
 
 position 
13C NMR 
(125 MHz) 
1H NMR 
(CD3OD, 600 MHz) 
1 124.1  
2 129.7 7.73 (1H, d, 2.4) 
3 130.6  
4 158.7  
5 115.5 6.83 (1H, d, 8.3) 
6 128.4 7.70 (1H, dd, 8.3, 2.4) 
7 29.1 3.34 (2H, overlapped) 
8 123.1 5.34 (1H, overlapped with H-3’”) 
9 133.8  
10 17.9 1.74 (3H, s)  
11 26.0 1.75 (3H, s) 
12 169.4  
1ʹ 159.1  
2ʹ 103.2  
3’ 163.4  
4’ 123.2 7.77 (1H, d, 8.8) 
5’ 111.6 7.21 (1H, d, 9.0) 
6’ 160.8  
7ʹ 112.4  
8ʹ 151.5  
9' 114.8  
10’ 8.7 2.29 (3H, s) 
1” 99.9 5.57 (1H, d, 2.4) 
2” 70.9 4.23 (1H, t, 2.8) 
3” 73.0 5.32 (1H, dd, 9.8, 3.2) 
4” 82.6 3.57 (1H, d, 9.8, overlapped with H-
8”) 
5” 79.9  
6” 29.0 1.34 (3H, s) 
7” 23.2 1.14 (3H, s) 
8” 61.9 3.55 (3H, s) 
9” 157.5  
O O O
H
N
OH
O
O
OH
O
MeO
OH
H2N O
1
2
3
4
5
6
7
8
9
10
11
12
1'
2'
3'4'
5'
1"
2"3"4"
5"
6"
7"8"
9"
7'
8'
9'
 
3 
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Table 3  NMR Spectroscopic Data (CDCl3) for 4  
 
 
position 1H NMR  
(CDCl3, 400 MHz) 
3 3.50- 3.66 (2H, m) 
4 1.87- 2.07 (2H, m) 
5 2.33- 2.40 (1H, m) 
1.87- 2.07 (1H, m) 
6 4.06 (1H, t, 7.1) 
9 3.92 (1H, br s) 
10 2.62 (1H, m) 
11 0.89 (3H, d, 6.6) 
12 1.04 (3H, d, 7.1) 
  
 
 
 
Table 4  NMR Spectroscopic Data (CDCl3) for 5  
position 13C NMR 
(125 MHz) 
 
1H NMR 
(400 MHz) 
 
 
 1 173.1  
3 55.2 3.56 (1H, dd, 12.7,4.4) 
3.34 (1H, d, 12.7) 
4 69.1 4.36 (1H, t, 4.3) 
5 38.2 2.18 (1H, qt, 14.6, 5.1, 1.5) 
1.99 (1H, m) 
6 58.7 4.44 (1H, dddd, 12.44, 11.0, 5.1, 1.5) 
7 169.0  
9 54.6 4.08 (1H, m) 
 10 39.4 1.78 -1.85 (1H, m) 
1.41 (1H, m) 
11 25.8 1.78 -1.85 (1H, m) 
12 22.2 0.86 (3H, d, 2 ) 
13 23.3 0.87 (3H, d, 2 ) 
HN
N
O
O
1
2 3
4
5
7
8
910
11
12
Cyclo (Pro-Val)
 
HN
N
O
O
OH
1
2 3
4
56
7
8
9
10
Cyclo (L-Hyp-L-Leu)
11
12
13
 
4: Cyclo (D-Pro-L-Val) 
 
5: Cyclo (L-Hyp-L-Leu) 
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Table 5  NMR Spectroscopic Data (CDCl3) for 6  
position 13C NMR 
(125 MHz) 
 
1H NMR  
(500 MHz) 
 
 
1 164.9  
3 54.3 3.79 (1H, dd, 13.4, 4.4) 
3.55 (2H, d, 13.2) 
4 68.4 4.61 (1H, t, 4.5) 
5 37.9 2.40 (1H, m) 
2.12 (1H, dd, 4.1, 1.7) 
6 57.1 4.46 (1H, dd, 11.2, 6.1) 
7 169.9  
9 60.4 4.00 (1H, s) 
10 35.1 2.32 (1H, m) 
11 24.1 1.60 (2H, br s) 
12 12.1 0.93 (3H, t, 7.5) 
13 15.9 1.05 (3H, d, 7.5) 
 
 
 
Table 6  NMR Spectroscopic Data (CDCl3) for 7  
No. 13C NMR 
(125 MHz) 
 
1H NMR 
(500 MHz) 
 
 1 165.4  
3 54.6 3.76 (1H, dd, 13.2, 4.4) 
3.58 (1H, br d, 13.0) 
4 68.5 4.55 (1H, t, 4.25) 
5 37.9 2.34 (1H, dd, 13.4, 6.1) 
2.01 (1H, m) 
6 57.6 4.44 (1H, dd, 11.3, 6.1) 
7 169.9  
9 56.3 4.31 (1H, dd, 10.1, 3.6) 
10 36.9 3.61 (1H,dd, 14.4, 3.4) 
2.78 (1H, dd, 14.4, 10.4) 
1ʹ 136.0  
2ʹ 129.5 7.23a (2H, d, 1.7) 
3ʹ 129.4 7.35a (2H, d, 7.3) 
4ʹ 127.8 7.29 (1H, d, 7.1) 
HN
N
O
O
OH
1
2 3
4
56
7
8
910
11
12
13
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7: Cyclo (L-Hyp-L-Phe) 
 
6: Cyclo (D-Hyp-L-Ile) 
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Table 7 NMR Spectroscopic Data (CDCl3) for 8 and 9 
position Compound 8  
 
Compound 9 
 13C NMR 
(125 MHz) 
 
1H NMR (HMQC) 
(CDCl3, 500 MHz) 
 
 
 
 
 
13C NMR 
(125 MHz) 
 
1H NMR (HMQC) 
(CDCl3, 600 MHz) 
 
 
1 216.6  216.9  
2 40.5 2.64 (1H, pent, 6.2) 45.1 2.45 (1H, pent, 6.4) 
3 42.6 1.88-1.95 (3H, m) 
1.60 (4H, m) 
39.4 1.07-1.22 (2H, m) 
1.96 (1H, m) 
 
4 26.7 2.20 (1H, m) 31.5 2.04 (2H, m) 
5 32.9 1.88-1.95 (3H, m) 36.9 2.70-2.80 (2H, m) 
2.28 (2H, m) 
 
6 50.1 2.50 (2H, m) 55.3 2.34 (4H, m) 
1’ 66.5 4.21 (1H, d, 10.5) 68.9 3.78 (1H, m) 
2’ 38.2 1.60 (4H, m) 38.7 1.41 (1H, m) 
1.58 (1H, m) 
 1” NH 7.84 (1H, s) NH  
2” 172.1  172.1  
3” 38.5 2.79 (4H, dd, 16.5, 1.9) 
 
38.4 2.70-2.80 (2H, m) 
2.28 (2H, m) 
 4” 27.5 2.35 (3H, m) 26.9 2.52 (1H, hext) 
5” 37.2 2.79 (4H, dd, 16.5, 1.9) 44.9 1.07-1.22 (2H, m) 
2.04 (2H, m) 
 6” 171.9  171.9  
2-Me 14.2 0.99 (6H, dd, 6.4, 1.1) 14.0 0.99 (3H, d, 6.4) 
4-Me 18.3 1.23 (6H, dd, 7.3, 1.0) 21.1 0.98 (3H, d, 6.4) 
 
O OH
N
H
O O
1
3 5
1' 2'
1"
4"
6"
  
O OH
N
H
O O
1
3 5
1'
2'
1"
2"
4"
6"
 
8: Cycloheximide 9: Isoycloheximide 
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Table 8 NMR Spectroscopic Data (CDCl3) for 10  
position 13C NMR 
(125 MHz) 
1H NMR 
(DMSO, 400 MHz) 
 
 2 166.0  
3 55.3 3.90 
5 165.9  
6 55.0 3.90 
7 38.1 2.18 ( ) 
2.50-2.58 (m) 
 8 
38.5 
1’ 136.2  
2’ 
 
129.4 7.02 (2H, d, 6.8) 
3’ 127.9 7.20-7.27(3H, m) 
4’ 126.1 7.20-7.27(m) 
1” 131.5  
2” 130.5 6.83 (2H, d, 8.5) 
3” 114.7 6.66 (2H, d, 8.5) 
4” 155.7  
 
 
Table 9 NMR Spectroscopic Data (CDCl3) for 11  
position 1H NMR  
(CDCl3, 400 MHz) 
 
 
2  
3 4.20 (1H, m) 
5  
6 3.02 (1H, dd, 10.4, 6.1) 
7 2.20 (1H, m ) 
1.82 (m) 
8 1.94 ( m) 
1.82 ( m) 
9 3.63 (1H, m) 
3.41 (1H, m) 
 10 3.10 (2H, m) 
1’  
2’ 7.20 () 
3’  
7.31 (3H, m) 4’ 
HN
N
O
O
1
2
3
5
6
8
910
1'
2'4'
5'
 
NH
HN
O
O
OH123
5 6
7
8
1'
2'
3'
4' 1'' 2''
3''
4''
 
11: Cyclo (L-Pro-L-Phe) 
 
10: Cyclo (L-Phe-L-Tyr) 
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Table 10  NMR Spectroscopic Data for 12 and 13 
No. 12a  13b  
δC, mult. δH (mult., J in Hz) δC, mult. δH (mult., J in Hz) 
1 31.7, CH2 1.62 (1H, m)  
1.45 (1H, m) 
30.4, CH2 1.23 (2H, s) 
2 27.4, CH2 1. 60 (1H, overlapped) 
1. 28 (1H, overlapped) 
26.5, CH2 
 
1.56 (1H, m) 
1.23 (1H, overlapped) 
3 74.4, CH 3.96 (1H, brs) 71.7, CH 3.95 (1H, t, 2.2) 
4 30.9, CH2 1.90 (1H, m)  
1.27 (1H, overlapped) 
29.4, CH2 1.70 (1H, m) 
1.50 (1H, overlapped) 
5 38.1, CH 1.63 (1H, m) 36.4, CH 1.65 (1H, m) 
6 27.6, CH2 1. 60 (1H, overlapped) 
1. 28 (1H, overlapped) 
26.4, CH2 1.56 (1H, m) 
1.23 (1H, overlapped) 
7 22.2, CH2 1.83 (1H, m)  
1.27 (overlap) 
21.1, CH2 1.80 (1H, m) 
1.78 (1H, m) 
8 42.1, CH 1.76 (1H, m) 40.9, CH 1.65 (1H, m) 
9 37.6, CH 1.65 (1H, m) 29.3, CH 1.23 (1H, m) 
10 36.3, C -- 35.1, C -- 
11 21.0, CH2 2.03 (1H, m)  
1.48 (1H, m) 
19.8, CH2 1.44 (2H, s) 
 
12 39.4, CH2 2.05 (1H, m)  
1.20 (1H, m) 
38.4, CH2 1.97 (1H, m) 
1.12 (1H, d, 10) 
13 53.4, C -- 52.2, C -- 
14 86.7, C -- 85.6, C -- 
15 41.0, CH2 2.77 (1H, dd, 18.3, 3.3)  
2.30 (1H, dd, 18.3, 3.3) 
40.5, CH2 2.71 (1H, br d, 18.6) 
2.35 (1H, dd, 18.6, 3.4)  
16 134.0, 
 
6.25 (1H, t, 2.7) 132.1, 
 
6.09 (1H, t, 2.5) 
17 145.1, C -- 144.0, C -- 
18 17.0, CH3 1.27 (3H, s) 16.6, CH3 1.27 (3H, s) 
19 24.6, CH3 1.0 (3H, s) 24.0, CH3 0.95 (3H, s) 
20 161.9, C -- 158.3, C -- 
21 73.5, CH2 5.14(1H, dd, 16.5, 1.6) 
5.00(1H, dd, 16.5, 1.6) 
71.6, CH2 4.97 (1H,d, 13.1) 
4.96 (1H,d, 13.1) 
22 112.0, 
 
6.00 (1H, brs) 112.4, 
 
5.95 (1H, s) 
23 177.3, C -- 174.4, C -- 
1’ 97.3, CH 4.81 (1H, d, 1.7) 97.2, CH 4.91 (1H, d, 1.5) 
2’ 70.3, CH 5.18 (1H, dd, 3.4, 1.7) 67.6, CH 4.02 (1H, m) 
3’ 80.7, CH 3.46 (1H, dd, 9.5, 3.4) 81.3, CH 3.41 (1H, dd, 9.1, 3.4) 
4’ 73.2, CH 3.35 (1H, t, 9.5) 71.8, CH 3.49 (1H, t, 9.1) 
5’ 70.0, CH 3.70 (1H, dq, 9.5, 6.4)  67.4, CH 3.71 (1H, dq, 9.1, 6.1) 
6’ 18.0, CH 1.23 (3H, d, 6.4) 17.6, CH3 1.29 (3H, d, 6.1) 
2’-OAc 20.8, CH3 2.07 (3H, s,) 56.9, CH3 3.48 (3H, s) 
2’C=O 172.0, C -- 170.2, C -- 
3’-OMe 58.0, CH3 3.4 (3H, s) 60.5, 
  
3.59 (3H, s) 
a Recorded in CD3OD at 500 MHz. b Recorded in CDCl3 at 500 MHz. 
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1H NMR (500 MHz) and 13C NMR (125 MHz) Spectra (CD3OD) for 12 
 
 
 
                HMQC spectra (CD3OD) for 12 
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Table 11 NMR Spectroscopic (CD3OD) Data for 14 
 
No. δC, mult. δH (mult., J in Hz) 
1 170.1, C  
2 110.5, C  
3 157.9, C  
4 111.1, CH 6.55 (1H, dd, 8.3, 1.0) 
5 133.9, CH 7.24 (1H, t, 8.3) 
6 106.8, CH 6.65 (1H, dd, 8.3, 1.0) 
7 160.1, C  
1’ 68.1, CH2 5.43 (2H, s) 
2’ 137.5, C  
3’ 129.4, CH 7.50 (2H, d, 7.5) 
4’ 129.0, CH 7.36 (2H, t, 7.5) 
5’ 129.2, CH 7.30 (1H, d, 7.5) 
Glucose moiety 
1’’ 100.6, CH 5.08 (1H, d, 7.3) 
2’’ 78.2, CH 3.56 (2H, m) 
3’’ 78.0, CH 3.34 (2H, m) 
4’’ 71.2, CH 3.34 (overlapped) 
5’’ 79.9, CH 3.56 (overlapped) 
6’’ 62.5, CH2 3.82 (1H, m) 
3.66 ( overlapped) 
 
 
Apiose moeity 
1’’’ 111.2, CH 5.37 (1H, d, 2.0) 
2’’’ 78.1, CH 3.94 (1H, d, 2.4) 
3’’’ 80.4, C  
4’’’ 75.2, CH2 3.66 (overlapped) 
3.88 (1H, m) 
5’’’ 65.7, CH 3.51 (2H, s) 
  
O
OH
O
O
O
OR
MeO
HO
H
H
1
3
5'''
7
1' 3'
5'
1''
5''
6''
1'''4'''
2'''
O
O O
O
HOH2C
HO
HO
O
OH
OHOH
HO
19
149
3
20
17
18
1
1'
8
5
23
2'3'
6'
O
H
 
 
Structures of 12-14 
12: R = COCH3 
13: R = H 
 
14 
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1H NMR (500 MHz) and 13C NMR (125 MHz) Spectra (CD3OD) for 14 
 
 
 
 
                 HMQC spectra for 14 
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Table 12 NMR Spectroscopic (CD3OD) Data for 15   
 
position 13C NMR 
(125 MHz) 
 
1H NMR  
(500 MHz) 
 
 
1 131.1 8.48 (1H, d, 8.0) 
2 128.5 7.93 (2H, m) 
3 134.0 8.17 (1H, t, 8.5) 
4 118.3 8.65 (1H, d, 9.2) 
4a 137.3  
5a 140.0  
5b 115.5  
6 126.9 8.75 (1H, d, 8.5) 
7 123.0 7.56 (1H, t, 7.7) 
8 135.4 7.93 (2H, m) 
9 114.3 7.82 (1H, d, 8.3) 
9a 147.8  
10a 135.1  
11 126.1 9.13 (1H, br s) 
11a 128.1  
N-CH3 40.7 5.10 (3H, s) 
N
H
N
CH3
1
2
3
4 5 6
7
8
9
10
5a 5b
9a10a
1111a
 
15: Cryptolepine 
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Table 13 NMR Spectroscopic (DMSO-d6) Data for 16 
 
position 13C NMR 
(125 MHz) 
 
1H NMR (HMQC) 
(600 MHz) 
 
 
2 156.0  
3 132.7  
4 176.9  
5 160.7  
6 98.2 6.18 (1H, d, 2.0) 
7 163.6  
8 93.3 6.39 (1H, d, 2.0) 
9 156.4  
10 103.5  
1’ 120.4  
2’ 130.4 7.96 (2H, d, 8.8) 
3’ 114.6 6.86 (2H, d, 8.8) 
4’ 159.4  
Sugar 1(Glucose) 
1” 100.8  5.29 (1H, d, 7.8) 
2” 73.7 3.00-3.70  
3” 75.8  
4” 69.4  
5” 75.2  
6” 66.4  
Sugar 2 (rhamnose) 
1”’ 100.3 4.35 (1H, br s) 
2”’ 69.9 3.00-3.70 
3”’ 70.1  
4”’ 71.3  
5”’ 67.8  
6”’ 17.3 0.99 (3H, d, 6.4) 
O
OH O
O
HO 2
34
5
6
7
8
O
OH
HO
HOO
OH
HO
HO
O
OH
1'
2'
3'
4'
9
10
1"3"
6"
5"
1'"
3'"
6'"
 16 
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   Table 14 NMR Spectroscopic (DMSO - d6) Data for 17 
 
position 13C NMR 
(125 MHz) 
 
1H NMR  
(DMSO, 400 MHz) 
 
 
 2 160.3  
3 132.7  
4 177.0  
5 155.9  
6 98.2 6.19 (1H, d, 2.0) 
7 163.7  
8 93.2 6.42 (1H, d, 2.0) 
9 159.5  
10 103.5  
1’ 120.4  
2’ 130.4 8.02 (2H, d, 8.8) 
3’ 114.6 6.87 (2H, d, 8.8) 
4’ 159.4  
Glucose 
1” 100.3  5.45 (1H, d, 7.2) 
2” 73.7 3.16 (2H, d, 4.4) 
3” 77.0 3.16 (2H, d, 4.4) 
4” 69.4 3.06 (2H, s) 
5” 75.9 3.06 (2H, s) 
6” 60.3 3.55 (1H, dd, 11.2, 5.2) 
3.30 (1H, m) 
        
O
OH O
O
HO 2
34
5
7
O
OH
HO
HO
HO
OH
1'
2'
3'
4'
9
10
1"3"
6"
5"
  17 
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Table 15  NMR Spectroscopic (CDCl3) Data for 18 
No. 13C NMR 
(125 MHz) 
 
1H NMR  
(500 MHz) 
 
 
2 86.3  
3 47.7 4.00 (1H, s) 
4 56.3 3.73 (1H, s) 
5 83.7  
5a 104.4  
6 158.3  
7 92.8 5.99 (1H, d, 2.4) 
8 161.3  
9 93.4 5.44 (1H, d, 2.4) 
9a 154.0  
10 90.5  
11 174.0  
13 38.6 3.30 (m);  
2.22 (m) 
14 25.6 1.50 (m) 
15 26.8 1.50 (m) 
 
16 39.3 3.30 (m);  
18 169.3  
19 133.1  
20 133.2 6.30 (2H, dt, 12.2, 6.1, 1.3) 
21 59.5 4.21 (2H, dd, 6.1, 1.3) 
22 13.1 1.80 (3H, d, 1.2) 
1’ 128.6  
2’/6’ 128.7 7.61 (2H, d, 8.8) 
3’/5’ 113.7 6.99 (2H, d, 8.8) 
4’ 159.9  
1’’ 135.3  
2’’/6’’ 127.1 6.68 (2H, m) 
3’’/5’’ 127.1 6.92 (m) 
4’’ 125.8 6.92 (m) 
OMe-6 56.1 3.89 (3H, s) 
OMe-8 55.3 3.48 (3H, s) 
OMe-4’ 55.3 3.86 (3H, s) 
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   1H NMR (400 MHz) and 13C NMR (125 MHz) Spectra (CDCl3) for 18 
   
 
 
 
HMQC spectra (CD3OD) for 18 
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Table 16  NMR Spectroscopic (CDCl3) Data for 19 and 20 
 
 
position 
19 20 
13C NMR 
(100 MHz) 
 
1H NMR  
(400 MHz) 
 
 
13C NMR 
(125 MHz) 
 
1H NMR  
(600 MHz) 
 
 
1 48.1 2.06 (1H, m) 
0.95 (1H, m) 
45.8 1.74 (dd,14.0, 5.2) 
1.52 (1H, dd,14.0, 5.2) 
2 65.7 3.82 (1H, tt, 11.4, 4.1) 67.9 4.14 (1H, quintet, 5.2) 
3 51.1 1.74 (1H, m) 
1.12 (1H, t, 12.0) 
46.7 1.62 (3H, m) 
1.45 (1H, dd,14.0, 3.3) 
4 35.0  33.0  
5 54.9 1.07 (1H, dd, 12.4, 2.8) 53.2 1.16 (dd, 12.4, 2.8) 
6 23.9 1.28 (1H, m) 
1.25 (1H, m) 
24.5 1.74 (dd,14.0, 5.2) 
1.39 (1H, dd,12.9, 4.1) 
7 38.1 1.98 (1H, m) 
2.39 (1H, m) 
38.1 1.97 (1H, m) 
2.38 (1H, m) 
8 147.7  147.9  
9 56.4 1.67 (1H, m) 57.1 1.62 (3H, m) 
10 41.0  39.6  
11 22.5 1.70 (1H, m) 
 
22.8 1.62 (3H, m) 
1.57 (1H, m) 
 12 30.1 2.35 (1H, m) 
1.98 (1H, m) 
 
30.3 2.38 (2H, m) 
1.97 (2H, m) 
13 146.9  147.1  
14 139.0 6.34 (1H, dd, 17.6, 10.7) 139.1 6.35 (1H, dd, 17.6, 10.8) 
15 113.3 5.20 (1H, d, 17.6) 
5.02 (1H, d, 10.7) 
 
113.2 5.20 (1H, d, 17.6) 
5.02 (1H, d, 10.8) 
 16 115.6 4.97 (2H, d,10.7) 
 
115.6 4.97 (2H, d,10.8) 
 
17 107.2 4.56 (1H, d, 1.4) 
4.87 (1H, d, 1.4) 
107.0 4.56 (1H, s) 
4.86 (1H, s) 
18 33.7 0.92 (3H, s) 33.3 0.90 (6H, s) 
19 22.6 0.82 (3H, s) 24.6 0.96 (3H, s) 
20 15.4 0.70 (3H, s) 17.4 0.90 (6H, s) 
 
 
HO
H
2
 
19: 2β-OH (New)
20: 2α-OH (New)  
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   1H NMR (400 MHz) and 13C NMR (100 MHz) Spectra (CDCl3) for 19 
 
 
 
 
 
 
 
1H NMR (400 MHz) and 13C NMR (125 MHz) Spectra (CDCl3) for 20 
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                 HMQC spectra (CDCl3) for 19 
 
 
                   HMBC spectra (CDCl3) for 19 
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Table 17  NMR Spectroscopic (CDCl3) Data for 21 
 
position 
13C NMR 
(125 MHz) 
 
1H NMR  
(800 MHz) 
 
 
1 33.5 1.86 ( dt, 13.9, 3.8) 
1.58 ( m) 
 2 38.1 2.71 (1H, dt, 13.9, 6.4) 
2.27 (1H, dq,13.9, 2.3) 
3 218.6  
4 54.9  
5 42.6 2.15 ( 1H,dd, 12.4, 4.2) 
6 20.9 1.52 ( m);  
1.20 (m) 
7 28.2 1.32 (m) 
1.58 
 8 47.7 1.52 ( m) 
 9 21.1  
10 25.5  
11 26.7 2.06 (m);  
1.20 (m) 
12 31.9 1.52 ( m) 
 
 13 45.2  
14 48.8  
 15 35.4 1.23 (m) 
16 25.6 1.23 (m) 
1.71 
17 46.5 1.92 ( m) 
 18 18.4 1.02 (3H, s) 
19 29.6 0.82 (1H, d, 4.2 ) 
0.60 (1H, d, 4.2 ) 
 20 42.7 1.58 (m) 
21 62.5 3.77 (1H, dd, 11.2, 3.2) 
3.60 (1H, dd, 11.2, 5.2) 
 
 
22 26.5 1.50 ( m) 
23 27.7 1.58 ( m) 
 24 78.9 3.37 (1H, dd, 10.6, 1.8) 
25 73.1  
26 23.3 1.17 (3H, s) 
27 26.6 1.22 (3H, s) 
28 65.2 3.44 (1H, d, 11.9) 
3.73 (1H, d, 11.9) 
 
 29 15.9 1.08 (3H, s) 
30 19.4 0.92 (3H, s) 
O
CH2OH
H
HOH2C
H
OH
OH
21
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1H NMR (500 MHz) and 13C NMR (125 MHz) Spectra (CDCl3) for 21 
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Table 18  NMR Spectroscopic (CDCl3) Data for 22 
 
 
position 13C NMR 
(125 
 
 
1H NMR  
(500 MHz) 
 
 
1 39.1  
2 19.3  
3 42.2  
4 33.5  
5 55.6  
6 24.4  
7 38.4 2.34 (1H, m) 
1.95 (1H, m) 
8 148.7  
9 57.3  
10 39.9  
11 17.7  
12 41.4  
13 73.6  
14 145.3 5.88 (1H, dd, 17.3, 10.7) 
15 111.5 5.02 (1H, d, 10.7) 
5.19 (1H, d, 17.3) 
 16 27.7 1.25 (3H, s) 
17 106.5 4.79 (1H, s) 
4.49 (1H, s) 
18 33.6 0.84 (3H, s) 
19 21.7 0.77 (3H, s) 
20 14.4 0.65 (3H, s) 
1
4
5
810
11
12
13
14
15
16
17
1819
20
H
OH
 
22 
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Table 19  NMR Spectroscopic (CDCl3) Data for 23 
 
 
position 13C NMR 
(125 MHz) 
 
1H NMR  
(600 MHz) 
 
 
1 40.5 1.77 (1H, m) 
0.70 (1H, dd, 13.8, 4.2) 
2 18.7 1.60 (m); 1.35 (m) 
3 42.1 1.35 (m) 
1.11 (1H, dd, 14.4, 4.4) 
4 33.3  
5 56.0 0.76 (1H, dd, 12.0,1.8) 
6 19.2 1.50 (m); 1.26 (m) 
 
7 39.3 1.60 (m) 
 
8 48.9  
9 48.4 0.98 (1H, d, 7.8) 
10 39.5  
11 18.6 1.60 (m);1.35 (m) 
12 25.7 1.48 (m) 
 
13 41.2 2.53 (1H, m) 
14 43.9 2.09 (1H, d, 10.2) 
1.35 (m) 
15 136.1 5.33 (1H, d, 2.4) 
16 145.9  
17 61.4 4.16 (2H, dd, 5.4, 1.2) 
 
18 33.6 0.83 (3H, s) 
19 21.6 0.78 (3H, s) 
20 17.7 1.01 (3H, s) 
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Table 20  NMR Spectroscopic (CDCl3) Data for 24 
 
 
position 13C NMR 
(125 MHz) 
 
1H NMR  
(400 MHz) 
 
 
1 45.8 1.54 (4H, m) 
1.78 (1H, dd, 14.0, 5.1) 
2 67.9 4.14 (1H, m) 
3 46.6 1.43 (2H, dd, 14.0, 3.6) 
1.62 (1H, dddd, 20.1, 14.1, 6.0, 1.1) 
4 33.0  
5 53.2 1.13 (1H, dd, 13.6, 3.0) 
6 24.5 1.68 (3H, m) 
1.38 (2H, m) 
7 38.1 2.38 (1H, m) 
1.93 (1H, ddd, 25.5, 12.5, 5.0) 
8 148.0  
9 57.6 1.54 (4H, m) 
10 39.8  
11 18.2 1.54 (4H, m) 
1.38 (2H, m) 
12 41.4 1.68 (3H, m) 
1.29 (2H, m) 
13 73.6  
14 145.0 5.88 (1H, dd, 17.3, 10.7) 
15 111.7 5.19 (1H, dd, 17.3, 1.3) 
5.05 (1H, dd, 10.7, 1.3) 
16 28.0 1.26 (3H, s) 
17 107.1 4.82 (1H, d, 1.3) 
4.49 (1H, d, 1.3) 
18 24.6 0.97 (3H, s) 
19 33.3 0.90 (3H, s) 
20 17.3 0.89 (3H, s) 
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Table 21  NMR Spectroscopic (CDCl3) Data for 25 and 26 
 
 
position 
25 26 
13C NMR 
(125 MHz) 
 
1H NMR  
(500 MHz) 
 
 
13C NMR 
(125 MHz) 
 
1H NMR  
(500 MHz) 
 
 
1 79.3 6.14 (1H, d, 5.2) 78.9 4.91 (1H, dd, 5.2, 1.4) 
2 50.9 4.00 (1H, dd, 14.4, 5.2) 51.7 3.85 (m) 
3 56.1 4.32 (1H, d, 14.4) 56.2 4.23 (1H, d, 14.4) 
3a 101.9  101.6  
4a 160.8  161.1  
5 88.6 6.21 (1H, d, 2.0) 89.1 6.25 (1H, d, 1.7) 
6 164.2  164.1  
7 92.2 6.02 (1H, d, 2.0) 92.5 6.10 (1H, d, 1.7) 
8 158.8  157.3  
8a 106.0  106.9  
8b 92.3  93.5  
1’ 127.0  127.7  
2’/ 128.8 7.00 (m) 114.4 6.80 (1H, d, 2.2) 
3’/ 112.7 6.62 (d, 8.8) 144.6  
4’ 157.7  145.8  
5’ 112.7 6.62 (d, 8.8) 109.4 6.60 (1H, d, 8.4) 
6’ 128.8 7.00 (m) 119.7 6.68 (1H, dd, 8.4, 2.2) 
1” 136.1  136.3  
2”/6” 128.1 7.05-7.11 (m) 127.9 7.01-7.10 (5H, m) 
3”/5” 128.0 7.05-7.11 (m) 128.2 7.01-7.10 (5H, m) 
4” 126.5 7.05-7.11 (m) 126.9 7.01-7.10 (5H, m) 
COOH 170.2  172.5  
OCHO 159.6 7.95 (1H, s)   
Ar-OCH3 55.6 3.81 (3H, s) 55.8 3.84 (3H, s) 
 
 55.3 3.74 (3H, s) 55.8 3.81 (3H, s) 
 55.1 3.66 (3H, s) 55.7 3.76 (3H, s) 
 
O
OH
OMe
OMe
MeO COOH
OH
3
3a5
8a
7
1
2
8b
1'
4a
6
8
6'
3'
4'
2"
1"
4"
6"
HO
 
O
OH
OMe
OMe
MeO COOH
OCHO
3
3a
5 8a
7
1
2
8b
1'
2'
4a
6
8
3"
6'
5'3'
4'
2"
1"
4"
6"
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Table 22  NMR Spectroscopic (CD3OD) Data for 27 
 
position 13C NMR 
(150 MHz) 
 
1H NMR  
(600 MHz) 
 
 
1 172.1  
2 133.0  
3 135.8 6.34 (dt, 6.0, 1.4) 
4 59.5 4.23 (qd, 6.0, 0.8) 
5 13.0 1.83 (d, 1.4) 
1’ 40.3 3.29 (m) 
2’ 27.9 1.60 (m) 
3’ 27.9 1.60 (m) 
4’ 40.2 3.29 (m) 
1” 168.7  
2” 121.9 6.59 (d, 15.8) 
3” 141.6 7.51 (d, 15.8) 
4” 136.3  
5”/ 9” 128.8 7.55 (m) 
6”/ 8” 130.0 7.37 (m) 
 7” 130.8 7.37 (m) 
 
 
NH
O
OH
N
H
O
5
4
2
1"
4'
2"
1'
1
5"
3"
7" 9"  
27: Dasyclamide 
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Table 23 NMR Spectroscopic (CDCl3) Data for 28 
 
 
position 13C NMR 
(125 MHz) 
 
1H NMR  
(400 MHz) 
 
 
1 48.2  
2 65.7 3.86 (1H, tt, 11.5, 4.1) 
3 51.1 1.74 (1H, ddd, 12.0, 3.4, 2.4) 
1.12 (1H, t, 12.0) 
4 35.0  
5 54.8 1.07 (1H, dd, 12.7, 2.7) 
6 23.9  
7 38.0  
8 147.6  
9 56.2 1.62 (1H, br d, 11.2) 
10 41.0  
11 22.0  
12 30.1 2.14 (1H, m) 
2.06 (1H, dd, 4.1, 2.0) 
 13 140.3  
14 123.2 5.36 (1H, dt, 6.9, 1.2) 
15 59.4 4.12 (2H, d, 7.1) 
16 16.4 1.65 (3H, s) 
 17 107.2 4.83 (1H, d, 1.2) 
4.52 (1H, d, 1.2) 
 18 33.7 0.91 (3H, s) 
19 22.6 0.82 (3H, s) 
20 15.4 0.70 (3H, s) 
 
1
4
5
810
15
13
20
11
16
17
18
19
HO
OH
H
 
28 
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List of Bangladesh Plants Extracts 
 
KKB01 Adiantum phillipense (Leaves) 
KKB02 Asparagus racemosus (Roots) 
KKB03 Centella asiatica  (Whole plants) 
KKB04 Commelina benghalensis (Leaves) 
KKB05 Flemingia congesta  (Leaves) 
KKB06 Hygrophila spinosa  (Seed) 
KKB07 Mesua ferrea/ M. nagassarium  (Flower) 
KKB08 Ocimum sanctum  (Whole plant) 
KKB09 Sida acuta  (Whole plant) 
KKB10 Sida rhombifolia (Whole plant) 
KKB11 Vitex negundo (Leaves) 
KKB12 Derris indica (Leaves) 
KKB13 Derris trifoliata (Aerial parts) 
KKB14 Physalis minima 
KKB15 Exoecaria indica (Leaves) 
KKB16 Terminalia bellerica 
KKB17 Ficus racemosus (Fruits) 
KKB18 Ipomoea maxina 
KKB19 Cleome rutidosperma 
KKB20 Cricus arvensis 
KKB21 Acacia spp. 
KKB22 Heritiera fomes (Leaves) 
KKB23 
 
Xylocarpus granatum (Leaves) 
KKB24 Hibiscus tiliaceus  (Leaves) 
KKB25 Ceriops decandra (Leaves) 
KKB26 
 
Rhizophora spp. (Leaves) 
KKB27 Sonneratia caseolaris   (Leaves) 
KKB28 
 
Veronia spp. (Stem) 
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KKB29 
 
Lumnitzera racemosus  (Leaves) 
KKB30 Acanthus ilicifolius L. (Aerial parts) 
KKB31 Crataeva nurvala (Aerial parts) 
KKB32  Clerodendrum inerme   (Leaves) 
KKB33 Cerbera manghas  (Leaves) 
KKB34 Exocoecaria agallocha  (Leaves) 
KKB35 Avicennia marina (Leaves) 
KKB36 Ocimum gratissimum  (Aerial parts) 
KKB37  Thevetia peruviana   (Aerial parts) 
KKB38 Rhizophoria epiculata  (Leaves) 
KKB39 Amoora cucullata  (Leaves) 
KKB40 Rhizophora mucronata (Leaves) 
KKB41 Derris trifoliate  (Aerial parts) 
KKB42 Rhizophora mucronata  (Leaves) 
KKB43 Acrostichum aurium  (Aerial parts) 
KKB44 Cocculus villosus (Leaves with small stem) 
KKB45 Kandelia candela  (Leaves) 
KKB46 Aegiceras corniculatum (Leaves) 
KKB47  Renhydra sp.  (Aerial parts) 
KKB48 Curcuma zedoaria  (Aerial parts) 
KKB49 Mallotus spp. (Leaves with small stem) 
KKB50  Urginea indica  (Aerial parts) 
KKB51 Alombus  (Aerial parts) 
KKB52 Pongamia pinnata or Derris indica (Leaves) 
KKB53 Pongamia pinnata Merr. /Derris indica (Fruits) 
KKB54 Ocimum gratissimum  (Aerial parts) 
KKB55 Cyperus spp. (Whole Plant) 
KKB56 Pandanus  foetidus  Roxb. (Aerial parts) 
KKB57 Caesalpinia bonducella  (Aerial parts) 
KKB58 Dryopteris filiz-mus (Aerial parts) 
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KKB59 Avicennia officinalis  (Leaves with small stem) 
KKB60 Ricinus communis  (Stem) 
KKB61 Kandelia candel  (Leaves) 
KKB62 Sida rhombifolia (Whole plants) 
KKB63 Veronia spp.  (Aerial parts) 
KKB64 Acyranthes aspera L. (Aerial parts) 
KKB65 Cynometra remiflora  (Leaves) 
KKB66 Cynometra remiflora L. (Stem) 
KKB67 Altranthera spp. (Aerial parts) 
KKB68 Hedyotis corymbosa (Aerial parts) 
KKB69 Calotropis giguntea (Exudate) 
KKB70 Cassia fistula (Bark) 
KKB71  
KKB72  
KKB73 Polygonum spp. 
KKB74 Kijelia pinnata (Bark) 
KKB75 Excoecaria indica (Leaves) 
KKB76 Rhus succedanea  (Fruits)  
KKB77 Aglaia roxburghiana  (Seeds) 
KKB78 Semecarpus anacardium  (Fruits) 
KKB79 Baliospermum montanum  (Roots) 
KKB80 Leonurus sibiricus  (Whole plants) 
KKB81 Hemigraphis hirta  (Whole plants) 
KKB82 Pentapetes phoenicea (Aerial parts) 
KKB83 Cardiospermum halicacabum  (Aerial parts) 
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